

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
15 October 2020 (15.10.2020)



(10) International Publication Number  
**WO 2020/210512 A1**

(51) International Patent Classification:

*A61P 35/00* (2006.01)      *A61K 38/00* (2006.01)  
*A61P 35/04* (2006.01)      *C12N 15/85* (2006.01)  
*A61K 39/395* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2020/027498

(22) International Filing Date:

09 April 2020 (09.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/831,713      09 April 2019 (09.04.2019)      US

(71) Applicant: **ABCURO, INC.** [US/US]; 90 Bridge Street, Newton, MA 02458 (US).

(72) Inventors: **GULLA, Stefano, Vincenzo**; 12 Bradbury Ave, Medford, MA 02155 (US). **THOMPSON, Evan, Kenneth**; 34 Cypress Rd., Arlington, MA 02474 (US).

(74) Agent: **DECLoux, Amy, M.** et al.; Nutter McClennen & Fish LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2604 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES

(57) Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.



WO 2020/210512 A1

**KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1)  
DEPLETING ANTIBODIES**

## PRIORITY DATA:

[0001] This application claims the benefit of US Provisional Patent Application No.: 62/831,713, filed April 9, 2019, and is incorporated herein in its entirety.

## FIELD

[0002] The present disclosure relates to antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments of such antibodies, can be useful for various therapeutic or diagnostic purposes, including treatment of autoimmune diseases, cancers, and to increase the effectiveness of vaccines.

## BACKGROUND

[0003] Autoimmunity and Transplant

[0004] Cellular injury occurs in many diseases as a consequence of cytotoxic T cell attack. For example, pathogenic cytotoxic T cells are a key element in the destruction of muscle that occurs in the disease inclusion body myositis. Similar mechanisms of injury to tissues by cytotoxic T cells are implicated in other autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, autoimmune thyroid disease, type 1 diabetes, alopecia areata, Bechet's disease, ankylosing spondylitis, and primary biliary cirrhosis.

[0005] Similar mechanisms of injury are also present in solid organ transplantation, such as in graft versus host disease and organ rejection developing in the setting of transplantation associated with attack on tissues by CD8<sup>+</sup> T cells, where there are increased proportions of highly potent increased differentiated T cells, such as T effector memory (TEM) and T effector memory RA (TEMRA).

[0006] As described in PCT Application No. PCT/US2017/051776, killer cell lectin-like receptor G1 (KLRG1), a cell surface marker known to be present on senescent cytotoxic T cells, has been demonstrated by the inventors of the present disclosure to also be present on cytotoxic T cells with high-killing potential. For example, in the case of inclusion body

myositis, cell surface KLRG1 marks T cells that are directly killing healthy muscle cells. Unlike the teachings of prior studies regarding the senescent and inactive nature of KLRG1-expressing T cells in the blood of mice and humans, KLRG1-expressing T cells can be active and pathogenic, rendering them an advantageous target for cell depletion therapy.

[0007] Such cell depletion therapy comprises, in one example, administering to a subject in need thereof an effective amount of KLRG1 depleting agent (*e.g.*, a KLRG1 -expressing-cell depleting agent). The KLRG1 depleting agent can target the extracellular domain of KLRG1, comprising antibody dependent cellular cytotoxicity (ADCC) effector function, and can eliminate or reduce the number of cytotoxic T cells and/or NK cells injuring healthy cells.

[0008] Administering a KLRG1 depleting agent also can be effective in treating leukemias and lymphomas, which also involve the abnormal expansion of CD8+ T cells. In particular, T cell large granular lymphocytic leukemia (T-LGLL) is a leukemia characterized by expansion of late-stage differentiated CD8+ T cells, and NK cell lymphoproliferative disorder is a leukemia characterized by NK cell expansion. Extranasal NK/T cell lymphoma is a related disorder.

[0009] KLRG1 is type II transmembrane protein and is a co-inhibitory receptor modulating the activity of T and NK cells. Its extracellular portion contains a C-type lectin domain whose known ligands are cadherins and its intracellular portion contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) domain responsible for co-inhibition of T cell receptor (TCR) mediated signaling. In various embodiments, the ligand can be E-cadherin, N-cadherin, R-cadherin, or a combination thereof.

[0010] In association with its cadherin ligands, KLRG1 can function as a co-inhibitory receptor in a similar manner as a number of other T cell co-inhibitory receptors such as CTLA-4, PD-1, LAG-3, and TIM-3. Accordingly, KLRG1 is a favorable target for immunotherapy such as cancer immunotherapy. For example, administering to a subject in need thereof an effective amount of KLRG1/ligand binding agent can disrupt KLRG1 signaling and activate CD8+ cytotoxic T and/or NK cells. Thus, a KLRG1/ligand binding agent has numerous therapeutic uses, including for treating cancer, regardless of whether the cancer itself expresses KLRG1.

[0011] However, it has been observed that in patients with autoimmune diseases, cancer treatment with checkpoint inhibitor immunotherapy increases the risk of flares. These flares,

however, are associated with improved cancer outcomes. As indicated by Ted Bosworth in Rheumatology News in an article entitled “Checkpoint inhibitors in autoimmune disease: More flares, better cancer outcomes,” dated June 25, 2018, “[w]ith the initiation of checkpoint inhibitors, which were offered primarily for the treatment of melanoma (59%) and non–small cell lung cancer (36%), 42% of patients with PAD developed a disease flare. Of these, 30% were considered severe. ... However, those with a flare or another immune-related adverse event had significantly better progression-free survival ( $P = .016$ ) and overall survival ( $P = .004$ ) when compared with those who did not flare or have an immune-related adverse event.” Without being bound by theory, this study indicates that release of checkpoint inhibition activates CD8+ cytotoxic T and/or NK cells with all kinds of specificities in addition to tumor specificities, which may result in instigating or reactivating autoimmune disease in treated patients.

[0012] Therefore, there is a need in the art for adjunct therapy for cancer patients undergoing checkpoint therapy (regardless of whether the cancer expresses KLRG1), where the adjunct therapy comprises the use of a KLRG1 binding agent to deplete pathogenic T cells and/or NK cells attacking self-tissues, advantageously with no loss of T cells and/or NK cells directed to the cancer cells<sup>1</sup>.

[0013] Therefore, there is a need in the art for treating patients having a type of cancer wherein the cancer cells express KLRG1, where the treatment comprises the use of a KLRG1 binding agent to deplete cancer cells which express KLRG1, where the KLRG1 binding agent does not release the checkpoint inhibition and subsequent activation of pathogenic CD8+ cytotoxic T and/or NK cells directed to self-tissues.

[0014] Therefore, there is a need in the autoimmune art which uses a KLRG1 binding agent to deplete pathogenic T cells and/or NK cells attacking self-tissues, where the KLRG1 binding agent does not release the checkpoint inhibition and subsequent activation of pathogenic CD8+ cytotoxic T and/or NK cells directed to self-tissues.

[0015] Therefore, there is a need in the transplantation art which uses a KLRG1 binding agent to deplete pathogenic T cells and/or NK cells attacking transplanted tissues, where the KLRG1 binding agent does not release the checkpoint inhibition and subsequent activation of

---

<sup>1</sup> Applicant's working Example 6

pathogenic CD8+ cytotoxic T and/or NK cells directed to either transplanted or self-tissues or cells.

## SUMMARY

[0016] The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells which binds to ligands on epithelial and mesenchymal cells. The ligands for KLRG1 expressed on T and NK cells have been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure provides for the discovery and characterization of binding agents, such as antibodies, that bind the extracellular domain (ECD) of KLRG1, but do not interfere with its interaction with ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described herein have been derived by mouse hybridoma technology and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies provided for herein can be used as effective therapeutic agents.

[0017] Disclosed herein, among a number of different embodiments, is one exemplary embodiment of a method of depleting KLRG1 expressing T cells and/or NK cells in a subject in need of depletion treatment without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The method comprises delivering to a subject an effective amount of antibody, or a fragment of the antibody. The antibody, or fragment thereof, specifically binds to the extracellular domain of KLRG1 but does not compete with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, thereby depleting KLRG1 expressing T cells in the subject.

[0018] In some embodiments, the antibody, or a fragment thereof, can comprise a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. Alternatively, or additionally, the antibody, or a fragment thereof, can comprise a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0019] The KLRG1 can comprise human KLRG1 or Cyno KLRG1.

[0020] In some embodiments, the antibody, or a fragment thereof, can comprise a monoclonal antibody, or a fragment thereof. In some such instances, the monoclonal

antibody, or a fragment thereof, can specifically bind the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five (5) contiguous amino acids. The monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical to that sequence. Alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:10, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising an amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical to that sequence.

[0021] In some embodiments in which the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment thereof, the monoclonal antibody, or a fragment thereof, can comprise a chimeric antibody, or a fragment thereof. In some embodiments in which the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment thereof, the monoclonal antibody, or a fragment thereof, can comprise a humanized antibody or a fragment thereof.

[0022] Another exemplary embodiment of the present disclosure provides for a method of treating a disorder associated with excess KLRG1 expressing T cells in a subject in need of treatment. The method comprises delivering to a subject a therapeutically effective amount of an antibody, or a fragment of the antibody, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The delivery to the subject depletes KLRG1 expressing T cells, and does not release checkpoint inhibition and subsequent activation of pathogenic CD8+ cytotoxic T and/or NK cells directed to self-tissues, thereby treating the disorder. The antibody, or a fragment of the antibody, comprises a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. Alternatively, or additionally, the antibody, or a fragment of the antibody, comprises a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0023] In some embodiments, the disorder can comprise a transplant related disorder, and the delivery to the subject can deplete KLRG1 expressing pathogenic T cells and/or NK cells attacking transplanted tissues in the subject. Alternatively, the disorder can comprise an autoimmune disease, and the delivery to the subject can deplete KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject.

[0024] Still another exemplary embodiment of the present disclosure provides for a method of treating cancer in a subject, where the cancer comprises cancer cells that express KLRG1. The method comprises delivering to a subject a therapeutically effective amount of an antibody, or a fragment of the antibody, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The delivery to the subject depletes the cancer cells

expressing KLRG1, and the delivery does not release checkpoint inhibition and subsequent activation of pathogenic CD8<sup>+</sup> cytotoxic T and/or NK cells directed to self-tissues. The antibody, or a fragment of the antibody, comprises a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

Alternatively, or additionally, the antibody, or a fragment of the antibody, comprises a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0025] One, non-limiting exemplary embodiment of a therapy provided for in the present disclosure is an adjunct therapy for treatment of cancer in a subject in which the subject is undergoing checkpoint therapy. The method is performed regardless of whether the cancer expresses KLRG1. The adjunct therapy comprises delivering to a subject a therapeutically effective amount of an antibody, or a fragment of the antibody, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The delivery depletes KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject. The antibody, or a fragment of the antibody, comprises a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. Alternatively, or additionally, the antibody, or a fragment of the antibody, comprises a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0026] Also disclosed herein is one exemplary embodiment of a method of depleting KLRG1 expressing cells in a mixed population of cells in which the KLRG1 expressing cells comprise one or more cells selected from the group of T cells and/or NK cells and/or cancer cells. The method comprises delivering to a mixed population of cells an effective amount of an antibody, or a fragment of the antibody, that specifically binds to KLRG1 and depletes KLRG1 expressing T cells and/or NK cells and/or cancer cells, thereby depleting KLRG1 expressing T cells and/or NK cells and/or cancer cells in the mixed population of cells. The antibody, or a fragment of the antibody, comprises a heavy chain variable region comprising

three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.

Alternatively, or additionally, the antibody, or a fragment of the antibody, comprises a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0027] The present disclosure also provides exemplary embodiments of antibodies, or a fragment of such antibodies. One non-limiting exemplary embodiment of an antibody, or a fragment of the antibody, is one that specifically binds to an extracellular domain of KLRG1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1. The antibody, or fragment of the antibody, depletes cells expressing KLRG1 when administered to a subject.

[0028] In some embodiments, the antibody, or a fragment of the antibody, can comprise a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. Alternatively, or additionally, the antibody, or a fragment of the antibody, can comprise a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0029] The antibody, or a fragment of the antibody, can be such that the KLRG1 comprises human KLRG1 or Cyno KLRG1.

[0030] The antibody, or a fragment of the antibody, can comprise a monoclonal antibody, or a fragment or derivative thereof. In some such instances, the monoclonal antibody, or a fragment thereof, can specifically bind the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five (5) contiguous amino acids. The monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical to that sequence. Alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region

comprising the amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:10, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical to that sequence. Further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical to that sequence. Still further alternatively, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical to that sequence.

[0031] In some embodiments in which the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment thereof, the monoclonal antibody, or a fragment thereof, can comprise a chimeric antibody, or a fragment thereof. In some embodiments in which the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment thereof, the monoclonal antibody, or a fragment thereof, can comprise a humanized antibody or a fragment thereof.

[0032] A person skilled in the art will appreciate that many of the limitations provided for above can be applicable to each of the exemplary embodiments, as well as other embodiments provided for in the present disclosure. By way of non-limiting example, in any of the embodiments provided for in the present disclosure, the monoclonal antibody, or a fragment thereof, can comprise a humanized antibody, or a fragment thereof, or a chimeric antibody, or a fragment thereof.

[0033] The present disclosure also provides for exemplary pharmaceutical compositions. In one non-limiting exemplary embodiment, a pharmaceutical composition comprises one or more of an antibody, or fragment of the antibody, a monoclonal antibody, or a fragment of the antibody, or derivative of either such antibody or fragment, as disclosed herein (*e.g.*, the antibodies described above or otherwise provided for in the present disclosure, such as in claim 29), and a pharmaceutically acceptable carrier.

[0034] The present disclosure also provides for exemplary kits. In one non-limiting exemplary embodiment, a kit comprises one or more of an antibody, or fragment of the antibody, a monoclonal antibody, or a fragment of the antibody, or derivative of either such antibody or fragment, as disclosed herein (*e.g.*, the antibodies described above or otherwise provided for in the present disclosure, such as in claim 29), and instructions for use.

#### BRIEF DESCRIPTION OF DRAWINGS

[0035] This disclosure will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

[0036] FIG. 1 provides one exemplary embodiment of peptide mapping of binding epitope of ABC\_G1D03, showing binding of the antibody to a peptide sequence defined by the amino acids "PLNFSRI" (SEQ ID NO:56);

[0037] FIG. 2 provides a three-dimensional representation of KLRG1 (20) binding to E-cadherin (3) derived from the PDB crystal structure 3ff7, with a first highlighted region (40) corresponding to a binding site for ABC\_G1D03 defined by amino acids "PLNFSRI" (SEQ ID NO:56), on KLRG1, and a second highlighted region (50) corresponding to a binding interface between KLRG1 and E-cadherin;

[0038] FIG. 3 provides a table and resulting graph that illustrates activity of non-blocking KLRG1 blocking antibodies on CD8+ human T cells; in contrast with KLRG1 blocking antibodies (mAb23), non-blocking antibodies have low activity in stimulating interferon gamma release in human CD8 T cells;

[0039] FIG. 4 provides a graph illustrating KLRG1 expression on T cell subsets, with KLRG1 being differentially expressed on effector T cells (TEM and TEMRA), which are CCR7-, compared to naive T cells (TN and TCM), which are CCR7+;

[0040] FIG. 5 provides flow cytometry analysis of CD8 T cells from non-human primate whole blood, highlighting the depletion effect of ABC-HG1D03 on KLRG1+ T cells; of note is that KLRG1 positive cells correspond to the effector phenotype and ABC-HG1D03 results in full, yet selective, depletion of this compartment;

[0041] FIG. 6 provides a graph illustrating a dose dependent effect of ABC-HG1D03 on % KLRG1+ CD8 T cells in a non-human primate; and

[0042] FIG. 7 provides a graph illustrating a regulatory T cell sparing effect of ABC-HG1D03 in a non-human primate.

#### DETAILED DESCRIPTION

[0043] Certain exemplary embodiments will now be described to provide an overall understanding of the principles of the structure, function, manufacture, and use of the antibodies, fragments thereof, compositions of matter, kits, and related methods and therapies disclosed herein. Those skilled in the art will understand that the disclosures described herein and illustrated in the accompanying drawings are non-limiting exemplary embodiments and that the scope of the present disclosure is defined solely by the claims. The features illustrated or described in connection with one exemplary embodiment may be combined with the features of other embodiments. Such modifications and variations are intended to be included within the scope of the present disclosure.

[0044] Killer cell lectin-like receptor G1 (KLRG1) is a type II transmembrane protein which can function as co-inhibitory receptor by modulating the activity of T and NK cells. The extracellular portion of KLRG1 contains a C-type lectin domain whose known ligands are cadherins. The intracellular portion of KLRG1 contains an immunoreceptor tyrosine-

based inhibitory motif (ITIM) domain responsible for co-inhibition of T cell receptor (TCR) mediated signaling. KLRG1 ligands include E-cadherin, N-cadherin, R-cadherin, and combinations thereof.

[0045] The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells which bind to ligands on epithelial and mesenchymal cells. The ligands for KLRG1 can be E-cadherin, N-cadherin, and R-cadherin.

[0046] In humans, KLRG1 expression is generally confined to cells of the immune systems, and specifically to CD8 positive T cells, NK cells, and, to a lesser extent, CD4 positive T cells. KLRG1 expression has been associated with the late differentiated phenotype. As antigen specific T cells differentiate they can acquire increased expression of cytotoxic molecules, and therefore can have increased cytotoxic potential.

[0047] The present disclosure is based, at least in part, on the discovery described in PCT Application No. PCT/US2017/051776—that KLRG1, a cell surface marker known to be present on senescent cytotoxic T cells, is also present on cytotoxic T cells with high-killing potential. For example, in the case of inclusion body myositis, KLRG1 can mark T cells that are directly killing healthy muscle cells.

[0048] Thus, KLRG1-expressing T cells and/or NK cells can be pathogenic and are therefore an advantageous target for cell depletion therapy. For example, administering to a subject in need of an effective amount of KLRG1 depleting agent (*e.g.*, a KLRG1 -expressing-cell depleting agent) with antibody dependent cellular cytotoxicity (ADCC) effector function can eliminate or reduce the number of cytotoxic T cells and/or NK cells injuring healthy cells as, for example, in autoimmune diseases and in transplant disorders.

[0049] Methods comprising administering a KLRG1 -expressing-cell depleting agent are also advantageous in treating patients with cancer cells expressing KLGR1.

[0050] Markedly, the KLRG1 -expressing-cell depleting agents disclosed herein have the additional property of not interrupting KLRG1's function as a Lymphocyte co-inhibitory receptor(s) mediated by the binding of E-cadherin, N-cadherin, R-cadherin, or a combination thereof, to the extracellular domain of KLRG1.

[0051] A prominent biological function of cell surface KLRG1 is to inhibit cytotoxicity and proliferation of cytotoxic T cells and/or NK cells by functioning as a lymphocyte co-inhibitory receptor. Lymphocyte co-inhibitory receptors modulate the action of the adaptive immune system, *e.g.*, T cells and NK cells, in response to activating signals such as antigenic peptides in the context of the major histocompatibility complex (MHC) binding to the T cell receptor (TCR). Other co-inhibitory receptors known in the art include PD-1, LAG-3, TIM-3, and CTLA4. The action of co-inhibitory receptors can generally be carried out by binding a ligand to the extracellular domain of the co-inhibitory receptor, followed by recruitment of intracellular phosphatases by an immune-receptor tyrosine-based inhibition motif (ITIM) located in the intracellular domain of the co-inhibitory receptor. The action of co-inhibitory receptors is generally to dampen the immune response of TCR engagement.

[0052] By not interfering with the binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, the function of KLRG1 as a lymphocyte co-inhibitory receptor can be maintained. Because the KLRG1 binding agent does not release the checkpoint inhibition, the inhibition of the activation of potentially pathogenic CD8+ cytotoxic T and/or NK cells can be maintained.

[0053] Accordingly, the KLRG1 depleting agents, and related methods, disclosed herein not only deplete KLRG1 expressing T cells and/or NK cells in a subject, but additionally do not interfere with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The targeted depletion of KLRG1 expressing T cells and/or KLRG1 expressing NK cells and/or KLRG1 expressing cancer cells in a subject can be mediated by the fc region of the KLRG1 specific antibody or antigen binding fragment thereof and/or by an fc peptide conjugated to a KLRG1 specific antigen binding fragment thereof, and/or by a cytotoxic agent conjugated to a KLRG1 specific antibody or antigen binding fragment thereof. International Patent Application Publication No. WO 02/44215 describes binding molecules which comprise or consist of the antigen binding site of an antibody and a peptide binding Fc-effector molecule.

[0054] Selected Embodiments of the Present Disclosure

[0055] Disclosed herein are methods of depleting KLRG1 expressing T cells and/or NK cells in a subject in need of treatment, without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. Methods provided for herein

include delivering to a subject in need of treatment an effective amount of a KLGR1 depleting agent, such as an antibody, or a fragment thereof, that specifically binds to the extracellular domain of KLRG1 but does not compete with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, thereby depleting KLRG1 expressing T cells in the subject.

[0056] Also disclosed herein are methods of selectively depleting KLRG1 expressing CD8 effector T cells, but not naïve T cells or regulatory T cells, that includes delivering to a subject an effective amount of antibody, or a fragment thereof, such that the antibody, or fragment thereof, specifically binds to the extracellular domain of KLRG1 but does not compete with binding of at least one of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, thereby selectively depleting KLRG1 expressing CD8 effector T cells.

[0057] In some embodiments of the methods, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of an amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14, and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes the three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0058] In some embodiments of the methods, the KLRG1 can be human KLRG1 or Cyno KLRG1.

[0059] In some embodiments of the methods, the antibody, or a fragment thereof, includes a monoclonal antibody, or a fragment or derivative thereof. In some aspects, the monoclonal antibody, or a fragment thereof, can specifically bind the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five (5) contiguous amino acids. The monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include

the amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical thereto. 11. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:10, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can include a chimeric antibody, or a fragment thereof. In some aspects, the monoclonal antibody, or a fragment thereof, can include a humanized antibody, or a fragment thereof.

[0060] Disclosed herein are methods of treating a disorder associated with excess or unwanted KLRG1 expressing T cells in a subject in need of treatment in which the method includes delivering to the subject a therapeutically effective amount of a KLRG1 depleting agent. The KLRG1 depleting agent can include an antibody, or a fragment thereof, that specifically binds to the extracellular domain of KLRG1 without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, and can

deplete KLRG1 expressing T cells, with the delivery to the subject depleting the excess or unwanted KLRG1 expressing T cells. Such delivery can be performed in such a way that delivery does not release checkpoint inhibition and subsequent activation of pathogenic CD8<sup>+</sup> cytotoxic T and/or NK cells directed to self-tissues, thereby treating the disorder.

[0061] In some embodiments of the methods, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In some embodiments of the method, the disorder can be a transplant-related disorder, with the delivery to the subject depleting KLRG1 expressing pathogenic T cells and/or NK cells attacking transplanted tissues in the subject. In some embodiments of the method, the disorder can be an autoimmune disease, with the delivery to the subject depleting KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject.

[0062] Disclosed herein are methods of treating cancer in a subject, with the cancer including cancer cells that express KLRG1. The methods can include delivering to the subject a therapeutically effective amount of a KLRG1 depleting agent, such an antibody, or a fragment thereof, that specifically binds to the extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The delivery to the subject can deplete the cancer cells expressing KLRG1, and the delivery can do so while not releasing checkpoint inhibition and subsequent activation of pathogenic CD8<sup>+</sup> cytotoxic T and/or NK cells directed to self-tissues.

[0063] In some embodiments of the methods, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0064] Disclosed herein are adjunct therapies for treatment of cancer in a subject, such as subject that is undergoing checkpoint therapy. The methods can be performed regardless of whether the cancer expresses KLRG1. The provided for adjunct therapies can include delivering to the subject a therapeutically effective amount of a KLRG1 depleting agent, such as an antibody, or a fragment thereof, that specifically binds to the extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1. The delivery to the subject can deplete KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject.

[0065] In some embodiments of the methods, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0066] Disclosed herein are methods of depleting KLRG1 expressing cells in a mixed population of cells. The KLRG1 expressing cells can include one or more cells selected from a group consisting of T cells and/or NK cells and/or cancer cells. The method can include delivering to the mixed population of cells an effective amount of a KLRG1 depleting agent, such as an antibody, or a fragment thereof, that specifically binds to KLRG1 and depletes KLRG1 expressing T cells and/or NK cells and/or cancer cells, thereby depleting KLRG1 expressing T cells and/or NK cells and/or cancer cells in the mixed population of cells.

[0067] In some embodiments of the methods, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0068] Disclosed herein are KLRG1 depleting agents that specifically bind to an extracellular domain of KLRG1 but do not compete with E-cadherin, N-cadherin, or R-

cadherin binding to KLRG1, and deplete cells expressing KLRG1 when administered to a subject. The KLRG1 depleting agent can include an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1, and depletes cells expressing KLRG1 when administered to a subject.

[0069] In some embodiments, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or the antibody, or a fragment thereof, comprises a light chain variable region that includes three complementarity determining regions of the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In some embodiments, the KLRG1 can be human KLRG1 or Cyno KLRG1. In some embodiments, the antibody, or a fragment thereof, can include a monoclonal antibody, or a fragment or derivative thereof. In some embodiments, the monoclonal antibody, or a fragment thereof, can specifically bind the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five (5) contiguous amino acids. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that can include the amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that can include the amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that includes the amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that includes the amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that includes the amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that includes the amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that includes the amino acid sequence of SEQ ID NO:10, or a sequence

approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that includes the amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that includes the amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that includes the amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a heavy chain variable region that includes the amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can comprise a light chain variable region that includes the amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical thereto. In some aspects, the monoclonal antibody, or a fragment thereof, can include a chimeric antibody, or a fragment thereof. In some aspects, the monoclonal antibody, or a fragment thereof, can include a humanized antibody, or a fragment thereof. Disclosed herein are pharmaceutical compositions that include one or more of the above monoclonal antibodies, or a fragment thereof, and a pharmaceutically acceptable carrier. A person skilled in the art, in view of the present disclosure, will understand various pharmaceutically acceptable carriers that can be used, including but not limited to (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; (21) histidine buffered solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. Disclosed herein are also kits that can include one or more of the above monoclonal antibodies, or a fragment(s) thereof, and instructions for use. It will be appreciated that to the extent the term "fragment" is used herein, the fragment can also be more than one fragment, whether or not the term "fragment(s)" is used.

[0070] Definitions

[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art to which this present disclosure belongs. The terminology used in the description of the present disclosure herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the present disclosure and any invention(s) described or otherwise provided for herein.

[0072] Amino acids are represented herein by either the one-letter code, or the three-letter code, both in accordance with 37 C.F.R. §1.822 and established usage.

[0073] All publications, patent applications, patents, patent publications, and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.

[0074] As used in the description of the present disclosure and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0075] As used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

[0076] The terms "about" and "approximately" as used herein when referring to a measurable value such as an amount of polypeptide, dose, time, temperature, enzymatic activity or other biological activity and the like, is meant to encompass variations of  $\pm 20\%$ ,  $\pm 10\%$ ,  $\pm 5\%$ ,  $\pm 1\%$ ,  $+ 0.5\%$ , or even  $\pm 0.1\%$  of the specified amount.

[0077] The transitional phrase "consisting essentially of" means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim, "and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. *See In re Herz*, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in the original); *see also* MPEP § 2111.03.

[0078] The term "consists essentially of" (and grammatical variants), as applied to a polynucleotide or polypeptide sequence of this present disclosure, means a polynucleotide or

polypeptide that consists of both the recited sequence (*e.g.*, SEQ ID NO) and a total of ten or less (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) additional amino acids on the N-terminal and/or C-terminal ends of the recited sequence such that the function of polypeptide is not materially altered. The total of ten or less additional amino acids can include the total number of additional amino acids on both ends added together.

[0079] An "effective amount" as used herein is an amount that provides a desired effect. The term "effective amount" refers to a dosage or amount that is sufficient to reduce the activity of KLRG1 to result in amelioration of symptoms in a patient or to achieve a desired biological outcome, *e.g.*, reduced activity of KLRG1, modulation of lymphocyte co-inhibition response, increased or decreased activation of cytotoxic T and NK cells, or increased or decreased release of IFN $\gamma$  by cytotoxic T cells or NK cells.

[0080] A "therapeutically effective" amount as used herein is an amount that provides some improvement or benefit to the subject. Alternatively stated, a "therapeutically effective" amount is an amount that will provide some alleviation, mitigation, or decrease in at least one clinical symptom in the subject. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

[0081] By the terms "treat," "treating," or "treatment of," it is intended that the severity of the condition of the subject is reduced, or at least partially improved or modified, and that some alleviation, mitigation, or decrease in at least one clinical symptom is achieved.

[0082] The term "deplete" as used herein with respect to T cells and/or NK cells and/or KLRG1 expressing cancer cells refers to a measurable decrease in the number of said cells in a subject or in a sample. The reduction can be at least about 10%, *e.g.*, at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or more. In certain embodiments, the term refers to a decrease in the number of T cells and/or NK cells and/or KLRG1 expressing cancer cells in a subject or in a sample to an amount below detectable limits.

[0083] The term "autoimmune disorders" as used herein refers to any disorder associated with an autoimmune reaction. Examples include, without limitation, multiple sclerosis, Crohn's disease, ulcerative colitis, lupus, inflammatory bowel syndrome, and irritable bowel syndrome.

[0084] The term "cancer" as used herein refers to any benign or malignant abnormal growth of cells. Examples include, without limitation, breast cancer, prostate cancer, lymphoma, skin cancer, pancreatic cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma. In some embodiments, the cancer is selected from the group of tumor-forming cancers. A person skilled in the art will recognize which cancers fall within the purview of that group.

[0085] The term "transplant" refers to a section of tissue, or a complete organ, that is removed from its original natural site or host and transferred to a new position in the same person or in a separate individual. Methods for treating recipients of transplants relates to methods of inhibiting organ or tissue transplant rejection, particularly in mammals. More particularly, the present disclosure relates to methods of inhibiting transplant rejection in mammals in need thereof, which can include administering to such mammals a transplant rejection inhibiting amount of anti-KLRG1 binding agents, including antibodies which specifically bind KLRG1 and fragments thereof.

[0086] The term "isolated" can refer to a polypeptide that is substantially free of cellular material, viral material, and/or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an "isolated fragment" is a fragment of a polypeptide that is not naturally occurring as a fragment and would not be found in the natural state. "Isolated" does not mean

that the preparation is technically pure (homogeneous), but it is sufficiently pure to provide the polypeptide or nucleic acid in a form in which it can be used for the intended purpose. Thus, the term "isolated" refers to a molecule that is substantially free of its natural environment. For instance, an isolated protein is substantially free of cellular material or other proteins from the cell or tissue source from which it is derived. The term "isolated" also refers to preparations where the isolated protein is sufficiently pure to be administered as a pharmaceutical composition, or approximately at least 70-80% (w/w) pure, more preferably, approximately at least 80-90% (w/w) pure, even more preferably, approximately 90-95% pure; and, most preferably, approximately at least 95%, approximately at least 96%, approximately at least 97%, approximately at least 98%, approximately at least 99%, or approximately at least 100% (w/w) pure.

[0087] The term "fragment," as applied to a polypeptide, will be understood to mean an amino acid sequence of reduced length relative to a reference polypeptide or amino acid sequence and comprising, consisting essentially of, and/or consisting of an amino acid sequence of contiguous amino acids identical or almost identical (*e.g.*, approximately 90%, approximately 92%, approximately 95%, approximately 98%, approximately 99% identical) to the reference polypeptide or amino acid sequence. Such a polypeptide fragment according to the present disclosure may be, where appropriate, included in a larger polypeptide of which it is a constituent. In some embodiments, such fragments can comprise, consist essentially of, and/or consist of peptides having a length of at least about 4, about 6, about 8, about 10, about 12, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, 7 about 5, about 100, about 150, about 200, or more consecutive amino acids of a polypeptide or amino acid sequence according to the present disclosure.

[0088] As used herein, the terms "protein" and "polypeptide" are used interchangeably and encompass both peptides and proteins, unless indicated otherwise.

[0089] A "fusion protein" is a polypeptide produced when two heterologous nucleotide sequences or fragments thereof coding for two (or more) different polypeptides not found fused together in nature are fused together in the correct translational reading frame. Illustrative fusion polypeptides include fusions of a polypeptide of the present disclosure (or a fragment thereof) to all or a portion of glutathione s-transferase, maltose-binding protein, or a reporter protein (*e.g.*, Green Fluorescent Protein,  $\beta$ -glucuronidase,  $\beta$ -galactosidase, luciferase, etc.), hemagglutinin, c-myc, FLAG epitope, etc.

[0090] As used herein, a "functional" polypeptide or "functional fragment" is one that substantially retains at least one biological activity normally associated with that polypeptide (*e.g.*, target protein binding). In particular embodiments, the "functional" polypeptide or "functional fragment" substantially retains all of the activities possessed by the unmodified peptide. By "substantially retains" biological activity, it is meant that the polypeptide retains at least about 20%, about 30%, about 40%, about 50%, about 60%, about 75%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99%, or more, of the biological activity of the native polypeptide (and can even have a higher level of activity than the native polypeptide). A "non-functional" polypeptide is one that exhibits little or essentially no detectable biological activity normally associated with the polypeptide (*e.g.*, at most, only an insignificant amount, *e.g.*, less than about 10% or even less than about 5%). Biological activities such as protein binding can be measured using assays that are well known in the art and as described herein.

[0091] Antibodies and Compositions

[0092] The present disclosure allows for the identification and characterization of antibodies that specifically bind to the extracellular domain of KLRG1 of cells without interfering with the binding of E-cadherin, R-cadherin, and/or N-cadherin to the extracellular domain of KLRG1. Such antibodies can advantageously be used to deplete cells expressing cell surface KLRG1 in a subject, *e.g.*, for research or therapeutic purposes. Such antibodies can be used to treat disorders associated with pathogenic and autoimmune T cells as well as cancer cells expressing KLRG1. Accordingly, one aspect of the present disclosure relates to antibodies or fragments thereof that specifically bind to the extracellular domain of KLRG1 and depletes cells expressing KLRG1 when administered to a subject. Such antibodies, or fragments thereof, can be used as an adjunct therapy for cancer treatment, regardless if the cancer cells express KLRG1.

[0093] Intact antibodies, also known as immunoglobulins, are typically tetrameric glycosylated proteins composed of two light (L) chains of approximately 25 kDa each and two heavy (H) chains of approximately 50 kDa each. Two types of light chain, designated as the  $\lambda$  chain and the  $\kappa$  chain, are found in antibodies. Depending on the amino acid sequence of the constant domain of heavy chains, immunoglobulins can be assigned to five major classes: A, D, E, G, and M, and several of these may be further divided into subclasses (isotypes), *e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0094] The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known in the art. Briefly, each light chain can be composed of an N-terminal variable domain (VL) and a constant domain (CL). Each heavy chain can be composed of an N-terminal variable domain (VH), three or four constant domains (CH), and a hinge region. The CH domain most proximal to VH is designated as CH1. The VH and VL domains consist or comprise of four regions of relatively conserved sequence called framework regions (FR1, FR2, FR3, and FR4), which form a scaffold for three regions of hypervariable sequence called complementarity determining regions (CDRs). The CDRs can contain most of the residues responsible for specific interactions with the antigen. The three CDRs are referred to as CDR1, CDR2, and CDR3. CDR constituents on the heavy chain are referred to as H1, H2, and H3, while CDR constituents on the light chain are referred to as L1, L2, and L3, accordingly. CDR3 and particularly H3, are the greatest source of molecular diversity within the antigen-binding domain. H3, for example, can be as short as two amino acid residues of greater than 26.

[0095] The Fab fragment (Fragment antigen-binding), or Fab, consists or comprises of the VH-CH1 and VL-CL domains covalently linked by a disulfide bond between the constant regions. Known to those skilled in the art, a Fab (50,000 daltons) is a monovalent fragment that is produced from IgG and IgM, consisting or comprising of the VH, CH1 and VL, CL regions, linked by an intramolecular disulfide bond. To overcome the tendency of non-covalently linked VH and VL domains in the Fv to dissociate when co-expressed in a host cell, a so-called single chain (sc) Fv fragment (scFv) can be constructed. In a scFv, a flexible and adequately long polypeptide links either the C-terminus of the VH to the N-terminus of the VL, or the C-terminus of the VL to the N-terminus of the VH. Most commonly, a 15-residue (Gly4Ser)<sub>3</sub> peptide can be used as a linker, but other linkers are also known in the art.

[0096] Antibody diversity is a result of combinatorial assembly of multiple germline genes encoding variable regions and a variety of somatic events. The somatic events can include recombination of variable gene segments with diversity (D) and joining (J) gene segments to make a complete VH region and the recombination of variable and joining gene segments to make a complete VL region. The recombination process itself is imprecise, resulting in the loss or addition of amino acids at the V(D)J junctions. These mechanisms of diversity occur in the developing B cell prior to antigen exposure. After antigenic stimulation, the expressed antibody genes in B cells can undergo somatic mutation.

[0097] Based on the estimated number of germline gene segments, the random recombination of these segments, and random VH-VL pairing, up to approximately  $1.6 \times 10^7$  different antibodies can be produced according to Fundamental Immunology, 3<sup>rd</sup> ed., ed. Paul, Raven Press, New York, N.Y., 1993. When other processes which contribute to antibody diversity (such as somatic mutation) are taken into account, it is thought that upwards of approximately  $1 \times 10^{10}$  different antibodies could be potentially generated, as supported by Immunoglobulin Genes, 2<sup>nd</sup> ed., eds. Jonio et al., Academic Press, San Diego, Calif., 1995. Because of the many processes involved in antibody diversity, it is highly unlikely that independently generated antibodies will have identical amino acid sequences in the CDRs.

[0098] The present disclosure provides novel CDRs derived from human immunoglobulin gene libraries, which are effective in depleting cells expressing cell surface KLGR1. The scaffold structure for carrying a CDR can generally be, though is not limited to, an antibody heavy or light chain, or a portion thereof, in which the CDR is located at a location corresponding to the CDR of naturally occurring VH and VL. The structures and locations of immunoglobulin variable domains may be determined, for example, as described in Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md., 1991.

[0099] Depletion of KLGR1 Expressing Cells

[0100] Antibodies, such as those described herein, exhibit at least two functions in the immune system. They bind antigens, *e.g.*, KLRG1, and eliminate these antigens, including cells expressing the antigen, via the immunoglobulin effector functions, including but not limited to activation of the complement system or interaction with cellular receptors (Fc receptors) on phagocytic cells such as macrophages, and/or other immune cells such as NK cells, leukocytes, platelets, and placental trophoblasts.

[0101] Antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) are three well known antibody mediated mechanisms for killing, and thus depleting, target cells.

[0102] Though not bound by mechanism or theory, binding of the antibody to the target cell through the antigen binding region (variable domain) of the antibody can provide a linkage of the target cell to immune effectors through the Fc region(s) of the constant region

of the antibody. In ADCC, typically the fc region of the antibody binds to FcγRIIIa receptor on the immune effector cell, *e.g.*, an NK cell, which can then kill the target cell. In ADCP, typically the fc region of the antibody binds to FcγRIIa receptor on the immune effector cell, *e.g.*, a macrophage cell, which can then engulf and kill the target cell. CDC is induced when the immune complex C1q binds to the fc region of the antibody bound to the target cell, triggering the formation of a membrane attack complex that punches holes into the surface of the target cell.

[0103] Thus, the constant region of the antibody mediates effector functions, including the activation of complement and interaction with Fc receptors, enabling effects such as ADCC, ADCP, or CDC. Neither CH1 nor Cκ or Cλ domains mediate effector functions, which is the reason why Fabs do not show ADCC, ADCP, or CDC.

[0104] There are three classes of Fc gamma receptors, FcγRI (CD64), FcγRII (CD 32), and FcγRIII (CD 16). Only FcγRI is able to bind IgG in a monomeric form, and the affinity of FcγRI receptors compared to the immunoglobulin receptors FcγRII and FcγRIII is high. The high affinity receptor FcγRI is constitutively expressed on monocytes, macrophages, and dendritic cells, and expression can be induced on neutrophils and eosinophils. Thus, these cells can be recruited to a target cell through antibody or antibody fragment thereof comprising fc region, bound to the target cell.

[0105] The FcγRIIa receptor is found on macrophages, monocytes, and neutrophils, and the FcγRIIb receptor is found on B-cells, macrophages, mast cells, and eosinophils. The FcγRIIIa receptor is found on NK cells, macrophages, eosinophils, monocytes, and T cells, and the FcγRIIIb receptor is highly expressed on neutrophils. Again, these various cell types can be recruited to a target cell by an antibody bound to the target cell through an antibody or antibody fragment thereof comprising the fc region, bound to the target cell.

[0106] Thus, the KLRG1 binding molecules, including antibodies and antigen binding fragments thereof, and methods thereof, including those pertaining to KLRG1 depletion in a subject or *in vitro*, in some aspects comprise a KLRG1 antigen binding site together with an antibody constant domain or fragment thereof. This can function to mediate an effector function, including but not limited to ADCC, ADCP, or CDC. In some aspects the KLRG1 binding molecule consists or comprises of the antigen binding site of an antibody and a

peptide binding Fc-effector molecules, as described in International Patent Application Publication No. WO 02/44215.

[0107] Immunotoxins as Means for Depletion of KLGR1 Expressing Cells

[0108] In some aspects, the antibodies and/or antigen binding fragments thereof provided for by the instant disclosure are conjugated to a toxic agent, and thus do not necessarily rely on endogenous effector cells in ADCC, ADCP, or CDC to deplete the target cells, *e.g.*, pathogenic cells and/or cancer cells expressing cell surface KLGR1.

[0109] Immunoconjugates which include one or more cytotoxins are referred to as "immunotoxins." Antibodies conjugated to a cytotoxic agent, drug, or the like are also known as antibody-drug conjugates (ADC). An immunoconjugate may have a half-life of sufficient periods of time for the antibody-drug conjugate to be internalized, degraded, and induce cell killing by the released toxin. A cytotoxin or cytotoxic agent can include any agent that is detrimental to (*e.g.*, kills) cells. Suitable cytotoxic agents for forming immunoconjugates of the present disclosure include taxol, tubulysins, duostatins, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, maytansine or an analog or derivative thereof, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin; calicheamicin or analogs or derivatives thereof, antimetabolites (such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine, cladribine), alkylating agents (such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin; as well as duocarmycin A, duocarmycin SA, CC-1065 (a.k.a. rachelmycin), or analogs or derivatives of CC-1065), dolastatin, auristatin, pyrrolo[2,1-c][1,4]benzodiazepins (PDBs), indolinobenzodiazepine (IGNs) or analogues thereof, antibiotics (such as dactinomycin (formerly actinomycin), bleomycin, daunorubicin (formerly daunomycin), doxorubicin, idarubicin, mithramycin, mitomycin, mitoxantrone, plicamycin, anthramycin (AMC)), anti-mitotic agents (*e.g.*, tubulin-targeting agents), such as diphtheria toxin and related molecules (such as diphtheria A chain and active fragments thereof and hybrid molecules); ricin toxin (such as ricin A or a deglycosylated ricin A chain toxin), cholera

toxin, a Shiga-like toxin (SLT-I, SLT-II, SLT-IIIV), LT toxin, C3 toxin, Shiga toxin, pertussis toxin, tetanus toxin, soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin, alorin, saporin, modeccin, gelanin, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croton, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and enomycin toxins. Other suitable conjugated molecules include antimicrobial/lytic peptides such as CLIP, Magainin 2, mellitin, Cecropin, and P18; ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, diphtheria toxin, and Pseudomonas endotoxin.

[0110] Supplemental Therapeutic Agents

[0111] The antibodies of the present disclosure, including fragments thereof and conjugates thereof, can optionally be delivered to a patient in conjunction with other therapeutic agents. The additional therapeutic agents can be delivered concurrently with the antibodies of the present disclosure. As used herein, the word "concurrently" means sufficiently close in time to produce a combined effect (that is, concurrently can be simultaneously, or it can be two or more events occurring within a short time period before or after each other).

[0112] In some embodiments the antibodies of the present disclosure can be administered in conjunction with anti-cancer agents, such as: 1) vinca alkaloids (*e.g.*, vinblastine, vincristine); 2) epipodophyllotoxins (*e.g.*, etoposide and teniposide); 3) antibiotics (*e.g.*, dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (*e.g.*, L-asparaginase); 5) biological response modifiers (*e.g.*, interferon-alfa); 6) platinum coordinating complexes (*e.g.*, cisplatin and carboplatin); 7) anthracenediones (*e.g.*, mitoxantrone); 8) substituted ureas (*e.g.*, hydroxyurea); 9) methylhydrazine derivatives (*e.g.*, procarbazine (N-methylhydrazine; MIH)); 10) adrenocortical suppressants (*e.g.*, mitotane (o,p'-DDD) and aminoglutethimide); 11) adrenocorticosteroids (*e.g.*, prednisone); 12) progestins (*e.g.*, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate); 13) estrogens (*e.g.*, diethylstilbestrol and ethinyl estradiol); 14) antiestrogens (*e.g.*, tamoxifen); 15) androgens (*e.g.*, testosterone propionate and fluoxymesterone); 16) antiandrogens (*e.g.*, flutamide); and 17) gonadotropin-releasing hormone analogs (*e.g.*, leuprolide). In some embodiments the antibodies of the present disclosure can be administered in conjunction with anti-angiogenesis agents, such as antibodies to VEGF (*e.g.*,

bevacizumab (AVASTIN), ranibizumab (LUCENTIS)) and other promoters of angiogenesis (*e.g.*, bFGF, angiopoietin-1), antibodies to alpha-v/beta-3 vascular integrin (*e.g.*, VITAXIN), angiostatin, endostatin, dalteparin, ABT-510, CNGRC peptide TNF alpha conjugate, cyclophosphamide, combretastatin A4 phosphate, dimethylxanthenone acetic acid, docetaxel, lenalidomide, enzastaurin, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation (Abraxane), soy isoflavone (Genistein), tamoxifen citrate, thalidomide, ADH-1 (EXHERIN), AG-013736, AMG-706, AZD2171, sorafenib tosylate, BMS-582664, CHIR-265, pazopanib, PI-88, vatalanib, everolimus, suramin, sunitinib malate, XL184, ZD6474, ATN-161, cilengitide, and celecoxib.

[0113] In some embodiments, including but not limited to the treatment of an autoimmune disease or in transplantation treatment, the antibodies of the present disclosure can be administered in conjunction with immunosuppressive agents including, for example, cyclosporine A, rapamycin, glucocorticoids, azathioprine, mizoribine, aspirin derivatives, hydroxychloroquine, methotrexate, cyclophosphamide and FK506 (tacrolimus).

[0114] Antibody-Related Definitions

[0115] The term "antibody" or "antibodies" as used herein refers to all types of immunoglobulins, including IgG, IgM, IgA, IgD, and IgE. The antibody can be monoclonal or polyclonal and can be of any species of origin, including, for example, mouse, rat, rabbit, horse, goat, sheep, camel, or human, or can be a chimeric antibody. The antibodies can be recombinant monoclonal antibodies produced according to the methods disclosed, for example, in U.S. Patent No. 4,474,893 or U.S. Patent No. 4,816,567. The antibodies can also be chemically constructed, for example, according to the methods disclosed in U.S. Patent No. 4,676,980.

[0116] The terms "antigen-binding domain," "antigen-binding fragment," and "binding fragment" refer to a part of an antibody molecule that comprises amino acids responsible for the specific binding between the antibody and the antigen. In instances where an antigen is large, the antigen-binding domain may only bind to a part of the antigen. A portion of the antigen molecule that is responsible for specific interactions with the antigen-binding domain is referred to as "epitope" or "antigenic determinant."

[0117] Though an antigen-binding domain typically comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), however, it does not

necessarily have to comprise both. For example, a so-called Fd antibody fragment consists only of a VH domain, but still retains some antigen-binding function of the intact antibody.

[0118] Anti-KLRG1 antibodies may optionally comprise antibody constant regions or parts thereof. For example, a VL domain may have attached, at its C terminus, antibody light chain constant domains including human C $\kappa$  or C $\lambda$  chains. Similarly, a specific antigen-binding domain based on a VH domain may have attached all or part of an immunoglobulin heavy chain derived from any antibody isotope, *e.g.*, IgG, IgA, IgE, and IgM and any of the isotope sub-classes, which include but are not limited to, IgG1 and IgG4. The DNA and amino acid sequences for the C-terminal fragment of are well known in the art.

[0119] The term "repertoire" refers to a genetically diverse collection of nucleotides derived wholly or partially from sequences that encode expressed immunoglobulins. The sequences can be generated by *in vivo* rearrangement of, *e.g.*, V, D, and J segments for H chains and, *e.g.*, V and J segment for L chains. Alternatively, the sequences may be generated from a cell line by *in vitro* stimulation, in response to which the rearrangement occurs. Alternatively, part or all of the sequences may be obtained by combining, *e.g.*, unrearranged V segments with D and J segments, by nucleotide synthesis, randomized mutagenesis, and other methods, for example as disclosed in U.S. Patent No. 5,565,332.

[0120] The terms "specific interaction" and "specific binding" refer to two molecules forming a complex that is relatively stable under physiologic conditions. Specific binding can be characterized by a high affinity and a low to moderate capacity, as distinguished from non-specific binding, which usually has a low affinity with a moderate to high capacity. Typically, binding is considered specific when the affinity constant  $K_A$  is higher than approximately  $10^6 \text{ M}^{-1}$ , or more preferably higher than approximately  $10^8 \text{ M}^{-1}$ . If necessary, non-specific binding can be reduced without substantially affecting specific binding, for example, by varying the binding conditions. The appropriate binding conditions such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (*e.g.*, serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques.

[0121] In certain embodiments, the antibodies can specifically bind an epitope within the extracellular domain (ECD) of human or mouse or monkey KLRG1, with an affinity, as expressed in KD, of at least about 2 nM, about 1nM, about 100 pM, about 10 pM, or about 5

pM. The amino acid sequences of ECDs of human and cynomolgus KLRG1 are set out in SEQ ID NO:1 and SEQ ID NO:2, as listed in Working Example 1 below.

[0122] Antibody Binding Specificity

[0123] It is contemplated that antibodies of the present disclosure may also bind with other proteins, including, for example, recombinant proteins comprising all or a portion of KLRG1.

[0124] One skilled in the art will recognize that the antibodies of this present disclosure may be used to detect, measure, and inhibit proteins that differ somewhat from KLRG1. The antibodies can be expected to retain the specificity of binding so long as the target protein comprises a sequence which is at least about 60%, about 70%, about 80%, about 90%, about 95%, or more identical to any sequence of at least about 130, about 100, about 80, about 60, about 40, or about 20 of contiguous amino acids in the sequence set forth SEQ ID NO:1 or SEQ ID NO:2. The percent identity is determined by standard alignment algorithms such as, for example, Basic Local Alignment Tool (BLAST) described in Altschul et al. (1990) J. Mol. Biol., 215: 403-410, the algorithm of Needleman et al. (1970) J. Mol. Biol., 48: 444-453, or the algorithm of Meyers et al. (1988) Comput. Appl. Biosci., 4: 11-17.

[0125] In addition to the sequence homology analyses, epitope mapping (see, *e.g.*, Epitope Mapping Protocols, ed. Morris, Humana Press, 1996) and secondary and tertiary structure analyses can be carried out to identify specific 3D structures assumed by the disclosed antibodies and their complexes with antigens. Such methods include, but are not limited to, X-ray crystallography (Engstrom (1974) Biochem. Exp. Biol., 11:7-13) and computer modeling of virtual representations of the presently disclosed antibodies (Fletterick et al. (1986) Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

[0126] Antibody Variants

[0127] This disclosure also provides methods for obtaining an antibody specific for KLRG1. Complementarity-determining regions (CDRs) in such antibodies are not limited to the specific sequences of VH and VL identified in the Working Examples below, and may include variants of these sequences that retain the ability to specifically bind KLRG1 while not interfering with the binding by KLRG1 and E-cadherin, N-cadherin, and R-cadherin. Such variants may be derived from the sequences listed in the Working Examples by a skilled

artisan using techniques well known in the art. For example, amino acid substitutions, deletions, or additions, can be made in the framework regions (FRs) and/or in CDRs. While changes in the FRs can usually be designed to improve stability and immunogenicity of the antibody, changes in the CDRs can typically be designed to increase affinity of the antibody for its target.

[0128] Changes to FRs include, but are not limited to, humanizing a non-human derived or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site, *e.g.*, changing the class or subclass of the constant region, changing specific amino acid residues which might alter the effector function such as Fc receptor binding, *e.g.*, as described in U.S. Patent Nos. 5,624,821 and 5,648,260 and Lund et al. (1991) *J. Immun.* 147: 2657-2662 and Morgan et al. (1995) *Immunology* 86: 319-324, or changing the species from which the constant region is derived.

[0129] Variants of FRs also include naturally occurring immunoglobulin allotypes. Such affinity-increasing changes may be determined empirically by routine techniques that involve altering the CDR and testing the affinity antibody for its target. For example, conservative amino acid substitutions can be made within any one of the disclosed CDRs. Various alterations can be made according to the methods described, for example, in *Antibody Engineering*, 2<sup>nd</sup> ed., Oxford University Press, ed. Borrebaeck, 1995. These include but are not limited to nucleotide sequences that are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a “silent” change. For example, the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs (*see* Table 6). Furthermore, any native residue in the polypeptide may also be substituted with alanine (*see, e.g.*, MacLennan et al. (1998) *Acta Physiol. Scand. Suppl.* 643:55-67; Sasaki et al. (1998) *Adv. Biophys.* 35:1-24).

[0130] The phrase "substantially as set out" means that the relevant CDR, VH, or VL domain of the present disclosure will be either identical to, or have only insubstantial differences in the specified regions (*e.g.*, a CDR) from the sequence of which is set out.

Insubstantial differences include minor amino acid changes, such as substitutions of one (1) or two (2) out of any five (5) amino acids in the sequence of a specified region.

[0131] The term "KLRG1 activity" refers to one or more lymphocyte co-inhibitory activities associated with KLRG1. For example, KLRG1 activity may mean modulation of cytotoxic T and NK cell activation.

[0132] The term "modulate," and its cognates, refer to a reduction or an increase in the activity of KLRG1 associated with activation of T cells and NK cells due to its interaction with an anti-KLRG1 antibody, wherein the reduction or increase is relative to the activity of KLRG1 in the absence of the same antibody. A reduction or an increase in activity is preferably at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more. When KLRG1 activity is reduced, the terms "modulatory" and "modulate" are interchangeable with the terms "inhibitory" and "inhibit." When KLRG1 activity is increased, the terms "modulatory" and "modulate" are interchangeable with the terms "activating" and "activate."

[0133] Antibody fragments included within the scope of the present disclosure include, for example: Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; domain antibodies, diabodies; vaccibodies, linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. Such fragments can be produced by known techniques. For example, F(ab')<sub>2</sub> fragments can be produced by pepsin digestion of the antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries can be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (*see* Huse et al, Science 1989 Dec 8;246(4935):1275–1281).

[0134] Antibodies of the present disclosure may be altered or mutated for compatibility with species other than the species in which the antibody was produced. For example, antibodies may be humanized or camelized. Humanized forms of non-human (*e.g.*, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab1, F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-

human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin can be replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody can comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions (*i.e.*, the sequences between the CDR regions) are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also can comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0135] In certain embodiments, the VH and/or VL domains may be germlined, *i.e.*, the framework regions (FRs) of these domains are mutated using conventional molecular biology techniques to match those produced by the germline cells. In other embodiments, the framework sequences remain diverged from the consensus germline sequences.

[0136] Methods for humanizing non-human antibodies are well known in the art. The present disclosure, and any invention(s) provided for herein, is not limited to any particular source, species of origin, or method of production. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can essentially be performed following the method of Winter and co-workers (Jones et al, Nature 321:522 (1986); Riechmann et al, Nature 332:323 (1988); Verhoeyen et al, Science 239:1534 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues (*e.g.*, all of the CDRs or a portion thereof), and possibly some FR residues, are substituted by residues from analogous sites in rodent antibodies.

[0137] Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol. 227:381 (1991);

Marks et al, J. Mol Biol 222:581 (1991)). The techniques of Cole et al and Boerner et al are also available for the preparation of human monoclonal antibodies (Cole et al, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al, J. Immunol. 147:86 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, *e.g.*, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 9,434,782, 9,253,965, 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425, and 5,661,016, and in the following scientific publications: Lee, E-Chiang et al. "Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery" Nature Biotechnology volume 32, pages 356–363 (2014); Marks et al, Bio/Technology 10:779 (1992); Lonberg et al, Nature 368:856 (1994); Morrison, Nature 368:812 (1994); Fishwild et al, Nature Biotechnol. 14:M5 (1996); Neuberger, Nature Biotechnol 14:826 (1996); Lonberg and Huszar, Intern. Rev. Immunol 13:65 (1995).

[0138] Monoclonal antibodies used to carry out the present disclosure can be produced in a hybridoma cell line according to the technique of Kohler and Milstein, Nature 265:495 (1975). For example, a solution containing the appropriate antigen can be injected into a mouse and, after a sufficient time, the mouse sacrificed, and spleen cells obtained. The spleen cells can then be immortalized by fusing them, for example with myeloma cells or with lymphoma cells, typically in the presence of polyethylene glycol, to produce hybridoma cells. The hybridoma cells can then be grown in a suitable medium and the supernatant screened for monoclonal antibodies having the desired specificity. Monoclonal Fab fragments can be produced in *E. coli* by recombinant techniques known to those skilled in the art. Antibodies specific to the target polypeptide can also be obtained by phage display techniques known in the art.

[0139] Various immunoassays can be used for screening to identify antibodies having the desired specificity for the extracellular domain of KLRG1. Numerous protocols for competitive binding or immunoradiometric assays using monoclonal antibodies with established specificity are well known in the art. Such immunoassays typically involve the measurement of complex formation between an antigen and its specific antibody (*e.g.*,

antigen/antibody complex formation). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the polypeptides or peptides of this disclosure can be used as well as a competitive binding assay.

[0140] Further to the conjugates described above, anti-KLRG1 antibodies described herein can be conjugated to a solid support (*e.g.*, beads, plates, slides, or wells formed from materials such as latex or polystyrene) in accordance with known techniques. Anti-KLRG1 antibodies described herein can likewise be conjugated to detectable groups such as radiolabels (*e.g.*,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$  or  $^{99\text{m}}\text{Tc}$ , which may also be attached to antibodies using conventional chemistry), enzyme labels (*e.g.*, horseradish peroxidase, alkaline phosphatase), and fluorescence labels (*e.g.*, fluorescein) in accordance with known techniques. Detectable labels further include chemical moieties such as biotin, which may be detected via binding to a specific cognate detectable moiety, *e.g.*, labeled avidin. Determination of the formation of an antibody/antigen complex in the methods of this disclosure can be by detection of, for example, precipitation, agglutination, flocculation, radioactivity, color development or change, fluorescence, luminescence, etc., and is well known in the art.

[0141] As described above, anti-KLRG1 antibodies described herein can be linked to another functional molecule, *e.g.*, another peptide or protein (albumin, another antibody, etc.), toxin, radioisotope, cytotoxic or cytostatic agents. For example, the antibodies can be linked by chemical cross-linking or by recombinant methods. The antibodies may also be linked to one of a variety of nonproteinaceous polymers, *e.g.*, polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent No. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192, and 4,179,337. The antibodies can be chemically modified by covalent conjugation to a polymer, for example, to increase their circulating half-life. Exemplary polymers and methods to attach them are also shown in U.S. Patent Nos. 4,766,106, 4,179,337, 4,495,285, and 4,609,546.

[0142] Anti-KLRG1 antibodies described herein may also be altered to have a glycosylation pattern that differs from the native pattern. For example, one or more carbohydrate moieties can be deleted and/or one or more glycosylation sites added to the original antibody. Addition of glycosylation sites to the presently disclosed antibodies may be accomplished by altering the amino acid sequence to contain glycosylation site consensus sequences known in the art. Another means of increasing the number of carbohydrate moieties on the antibodies is by chemical or enzymatic coupling of glycosides to the amino

acid residues of the antibody. Such methods are described in International Patent Application Publication No. WO 87/05330, and in Aplin et al. (1981) *CRC Crit. Rev. Biochem.*, 22: 259-306. Removal of any carbohydrate moieties from the antibodies may be accomplished chemically or enzymatically, for example, as described by Hakimuddin et al. (1987) *Arch. Biochem. Biophys.*, 259: 52; and Edge et al. (1981) *Anal. Biochem.*, 118: 131 and by Thotakura et al.

[0143] Further Embodiments

[0144] In certain embodiments, the monoclonal antibody, or a fragment thereof, can be a chimeric antibody or a humanized antibody. In additional embodiments, the chimeric or humanized antibody comprises at least a portion of the CDRs of the monoclonal antibody. As used herein, a "portion" of a CDR is defined as one or more of the three loops from each of the light and heavy chain that make up the CDRs (*e.g.*, from 1-6 of the CDRs) or one or more portions of a loop comprising, consisting essentially of, or consisting of at least three contiguous amino acids. For example, the chimeric or humanized antibody may comprise 1, 2, 3, 4, 5, or 6 CDR loops, portions of 1, 2, 3, 4, 5, or 6 CDR loops, or a mixture thereof, in any combination.

[0145] In some embodiments, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes the amino acid sequence of any one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto. In some embodiments, the antibody, or fragment thereof, comprises a heavy chain variable region that includes at least 50 contiguous amino acids of the amino acid sequence of any one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 100 or about 150 or about 200 or more contiguous amino acids.

[0146] In some embodiments, the antibody, or a fragment thereof, comprises a light chain variable region that includes the amino acid sequence of any one of SEQ ID NOs: 5, 7, 9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto. In some embodiments, the antibody, or fragment thereof, comprises a light chain variable region that includes at least 50 contiguous amino acids of the amino acid sequence of any one of SEQ ID NOs: 5, 7,

9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 100 or about 150 or about 200 or more contiguous amino acids.

[0147] In some embodiments, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes the amino acid sequence of any one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto, and a light chain variable region that includes the amino acid sequence of any one of SEQ ID NOs: 5, 7, 9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto. In some embodiments, the antibody, or fragment thereof, comprises a heavy chain variable region that includes at least 50 contiguous amino acids of the amino acid sequence of any one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 100 or about 150 or about 200 or more contiguous amino acids, and a light chain variable region that includes at least 50 contiguous amino acids of the amino acid sequence of SEQ ID NOs: 5, 7, 9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 100 or about 150 or about 200 or more contiguous amino acids.

[0148] In some embodiments, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes at least one CDR (*e.g.*, 1, 2, or 3), or a portion thereof, from the amino acid sequence of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto. One of skill in the art understands that the CDRs play a role in binding specificity and that sequence substitutions (*e.g.*, for humanization of a mouse antibody) are typically made outside of the CDRs, and that minimal changes are typically made within the CDRs. Thus, in some embodiments, sequences that are approximately at least 90% identical to the disclosed sequences comprise no changes, or only a minimal number of changes, to the CDRs.

[0149] In some embodiments, the antibody, or a fragment thereof, comprises a light chain variable region that includes at least one CDR (*e.g.*, 1, 2, or 3), or a portion thereof, from the amino acid sequence of SEQ ID NOs: 5, 7, 9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto.

[0150] In some embodiments, the antibody, or a fragment thereof, comprises a heavy chain variable region that includes at least one CDR (*e.g.*, 1, 2, or 3), or a portion thereof, from the amino acid sequence of SEQ ID NOs: 4, 6, 8, 10, 12, 14, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto, and a light chain variable region that includes at least one CDR (*e.g.*, 1, 2, or 3), or a portion thereof, from the amino acid sequence of SEQ ID NOs: 5, 7, 9, 11, 13, 15, or a sequence approximately at least 90% identical thereto, *e.g.*, at least about 95%, about 96%, about 97%, about 98%, or about 99% identical thereto.

[0151] In further embodiments, the antibody can be a monoclonal antibody, or a fragment thereof, that competes for binding to the same epitope specifically bound by the monoclonal antibody ABC\_G1D01 or ABC\_G1D02 or ABC\_G1D03 or ABC\_G1D04 or ABC\_G1D05 or ABC\_G1D06. In still other embodiments, the antibody can be a monoclonal antibody, or a fragment thereof, that specifically binds to the same epitope specifically bound by the monoclonal antibody ABC\_G1D01 or ABC\_G1D02 or ABC\_G1D03 or ABC\_G1D04 or ABC\_G1D05 or ABC\_G1D06. In certain embodiments, the monoclonal antibody, or a fragment thereof, can be a chimeric antibody or a humanized antibody. In some embodiments, the chimeric or humanized antibody can include at least a portion of the CDRs of one of a monoclonal antibody ABC\_G1D01 or ABC\_G1D02 or ABC\_G1D03 or ABC\_G1D04 or ABC\_G1D05 or ABC\_G1D06.

[0152] Nucleic Acids, Cloning, and Expression Systems

[0153] The present disclosure further provides isolated nucleic acids encoding the disclosed antibodies. The nucleic acids may comprise DNA or RNA and may be wholly or partially synthetic or recombinant. Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.

[0154] The nucleic acids provided herein can comprise a coding sequence for a CDR, a VH domain, and/or a VL domain disclosed herein. The present disclosure also provides constructs in the form of plasmids, vectors, phagemids, transcription or expression cassettes which can include at least one nucleic acid encoding a CDR, a VH domain, and/or a VL domain disclosed herein. The disclosure further provides a host cell that can include one or more constructs as above.

[0155] Also provided are nucleic acids encoding any CDR (H1, H2, H3, L1, L2, or L3), VH or VL domain, as well as methods of making the encoded products. The methods can include expressing the encoded product from the encoding nucleic acid. Expression may be achieved, for example, by culturing under appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression a VH or VL domain, or specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate and as understood by a person skilled in the art.

[0156] Antigen-binding fragments, VH and/or VL domains, and encoding nucleic acid molecules and vectors may be isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function.

[0157] Systems for cloning and expression of a polypeptide in a variety of different host cells are well known in the art. For cells suitable for producing antibodies, *see* Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999. Briefly, suitable host cells include bacteria, plant cells, mammalian cells, and yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, NS0 mouse myeloma cells, and many others. A common bacterial host is *E. coli*. Any protein expression system compatible with the present disclosure may be used to produce the disclosed antibodies. Suitable expression systems include transgenic animals described in Gene Expression Systems, Academic Press, eds. Fernandez et al., 1999.

[0158] Suitable vectors can be chosen or constructed so that they contain appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes, and other sequences as appropriate. Vectors may be plasmids or viral, *e.g.*, phage, or phagemid, as appropriate. For further details *see*, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press, 1989. Many known techniques and protocols for manipulation of nucleic acid, for example, in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, 2<sup>nd</sup> Edition, eds. Ausubel et al., John Wiley & Sons, 1992.

[0159] Further aspects of the disclosure provide a host cell comprising a nucleic acid as disclosed herein, or otherwise derivable from the present disclosures. Still further aspects of the disclosure provide methods that include introducing such nucleic acid into a host cell. The introduction may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection, and transduction using retrovirus or other virus, *e.g.*, vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may include calcium chloride transformation, electroporation, and transfection using bacteriophage. The introduction of the nucleic acid into the cells may be followed by causing or allowing expression from the nucleic acid, *e.g.*, by culturing host cells under conditions for expression of the gene.

[0160] Pharmaceutical Compositions and Methods of Administration

[0161] The disclosure provides compositions comprising KLRG1 depletion agents, anti-KLRG1 antibodies, and/or fragments thereof, and/or conjugates and fusion proteins thereof. The compositions of the present disclosure can optionally comprise medicinal agents, pharmaceutical agents, carriers, pharmaceutically acceptable carriers, adjuvants, dispersing agents, diluents, and the like. Such compositions may be suitable for pharmaceutical use and administration to patients. By "pharmaceutically acceptable" it is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material can be administered to a subject without causing any undesirable biological effects such as toxicity. The compositions typically comprise one or more antibodies of the present disclosure and a pharmaceutically acceptable excipient. The phrase "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. The pharmaceutical compositions may also be included in a container, pack, or dispenser, together with instructions for administration.

[0162] The compositions of the present disclosure can be formulated for administration in a pharmaceutical carrier in accordance with known techniques. In the manufacture of a pharmaceutical formulation according to the present disclosure, the compound (including the

physiologically acceptable salts thereof) can typically be admixed with, *inter alia*, an acceptable carrier. The carrier can be a solid or a liquid, or both, and can be formulated with the compound as a unit-dose formulation, for example, a tablet, which can contain from approximately 0.01% or approximately 0.5% to approximately 95% or approximately 99% by weight of the compound. One or more compounds can be incorporated in the formulations of the present disclosure, which can be prepared by any of the techniques of pharmacy known to those skilled in the art.

[0163] A pharmaceutical composition of the present disclosure can be formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known to those skilled in the art. The administration may, for example, be intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, and/or transdermal. It may also be possible to obtain compositions that may be administered in other manners, including topically or orally, or which may be capable of transmission across mucous membranes.

[0164] Solutions or suspensions used for intradermal or subcutaneous application typically include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid, or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates, or phosphates; and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. Such preparations may be enclosed in ampoules, disposable syringes, or multiple dose vials, which can be made, for example, of glass or plastic.

[0165] Pharmaceutical compositions suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.), or phosphate buffered saline (PBS). Typically, the composition should be sterile and should be fluid to the extent that easy syringeability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Prevention of the action of microorganisms can

be achieved, for example, by various antibacterial and antifungal agents, including parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include in the composition isotonic agents, for example, sugars and/or polyalcohols, such as mannitol, sorbitol, and sodium chloride. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and/or by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate, and gelatin.

[0166] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets in some instances. For oral administration, the antibodies can be combined with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials, can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as microcrystalline cellulose, gum tragacanth, or gelatin; an excipient, such as starch or lactose; a disintegrating agent, such as alginic acid, Primogel, or corn starch; a lubricant, such as magnesium stearate or Sterotes; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; or a flavoring agent, such as peppermint, methyl salicylate, or orange flavoring.

[0167] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration may be accomplished, for example, through the use of lozenges, nasal sprays, inhalers, or suppositories. For example, in case of antibodies that include the Fc portion, compositions may be capable of transmission across mucous membranes in intestine, mouth, or lungs (*e.g.*, via the FcRn receptor-mediated pathway as described in U.S. Patent No. 6,030,613). For transdermal administration, the active compounds may be formulated, for example, into ointments, salves, gels, or creams as generally known in the art. For

administration by inhalation, the antibodies may be delivered, for example, in the form of an aerosol spray from pressured container or dispenser, which can contain a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[0168] In certain embodiments, the presently disclosed antibodies can be prepared with carriers that are configured to protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and/or polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions containing the presently disclosed antibodies can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0169] It may be advantageous to formulate oral or parenteral compositions in a dosage unit form for ease of administration and uniformity of dosage. The term "dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0170] Toxicity and therapeutic efficacy of the composition of the present disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD<sub>50</sub> (the dose lethal to approximately 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in approximately 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compositions that exhibit large therapeutic indices are typically preferred.

[0171] For any composition used in the present disclosure, or derivable from the present disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. Examples of suitable bioassays include but are not limited to DNA replication assays, cytokine release assays, transcription-based assays, KLRG1/cadherin binding assays, immunological assays, and other assays, such as those described in the Examples below. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. A dose may be formulated in animal models to achieve a

circulating plasma concentration range that includes the IC<sub>50</sub> (*i.e.*, the concentration of the antibody which achieves a half-maximal inhibition of symptoms). Circulating levels in plasma may be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage lies preferably within a range of circulating concentrations with little or no toxicity. The dosage may vary depending, at least in part, upon the dosage form employed and the route of administration utilized. Alternatively, one can administer the presently disclosed antibodies, or those derivable from the present disclosure, in a local rather than systemic manner, for example, in a depot or sustained-release formulation.

[0172] A further aspect of the present disclosure relates to kits for use in the methods provided for herein or otherwise derivable in view of the present disclosures. A kit can comprise one or more antibodies of the present disclosure, and/or one or more antibodies derivable from the present disclosure, in a form suitable for administration to a subject, and/or in a form suitable for compounding into a formulation. The kit can further comprise other components, such as therapeutic agents, carriers, buffers, containers, devices for administration, and the like. The kit can be designed for therapeutic use, diagnostic use, and/or research use, and the additional components can be those suitable for the intended use. A person skilled in the art will recognize various such components suitable for inclusion in kits of this nature. The kit can further comprise labels and/or instructions, *e.g.*, for treatment of a disorder. Such labeling and/or instructions can include, for example, information concerning the amount, frequency, and method of administration of the antibody. A person skilled in the art, in view of the present disclosures, will appreciate the types of instructions that may be included in conjunction as part of the kits. The instructions are provided for herein, or are otherwise derivable by a person skilled in the art in view of the present disclosures.

[0173] The following Working Examples do not in any way limit the scope of the present disclosure, and any invention(s) provided for herein. One of ordinary skill in the art will recognize the numerous modifications and variations that may be performed without altering the spirit or scope of the present disclosure. Such modifications and variations are encompassed within the scope of the present disclosure. The entire contents of all references, patents, and published patent applications cited throughout this application are herein incorporated by reference.

[0174] The phrase "disorder associated with KLGR1," as used herein, refers to any disease, disorder, or condition in which KLGR1 play a role in a cause, side effect, symptom, or other aspect in the disease, disorder, or condition. Examples of such disorders include, without limitation, autoimmune and transplantation disorders, and cancer.

[0175] **WORKING EXAMPLES**

[0176] **Example 1: Generation of anti-KLRG1 antibodies**

[0177] Production of recombinant antigens and proteins:

[0178] Recombinant proteins were produced by standard molecular cloning and expression protocols. The amino acid sequence of human KLRG1 ECD (SEQ ID NO:1), cyno KLRG1 ECD (SEQ ID NO:2) and human E-cadherin ECD (SEQ ID NO:3) are illustrated in Table 1.

[0179] Table 1: The amino acid sequence of human KLRG1 ECD (SEQ ID NO:1), cyno KLRG1 ECD (SEQ ID NO:2) and human E-cadherin ECD (SEQ ID NO:3)

human KLRG1 extracellular domain (ECD) (SEQ ID NO:1),	LCQGSNYSTCASCPCPDRWMKYGNHCYFVSVEEKDWNSSLEFCLARDSHLLVITDNQEM SLLQVFLSEAFCWIGLRNNSGWRWEDGSPLNFSRISSNSFVQTCGAINKNGLQASSCEVPL HWWCKKVRL
cyno KLRG1 extracellular domain (ECD) (SEQ ID NO:2),	LCQGSKYSTCASCPCPDHWMKYGNHCYFVSVEKKDWISSLEFCLARDSHLLMITDKQEM SLLQDFLSEAFHWVGLRNNSGWRWEDGSPLNFSRIYSNSLVQTCGAINKNSLQASSCEVSL QWVCKKVSP
human E-cadherin full length (SEQ ID NO:3)	DWVIPPISCPENEGPFPKNLVQIKSNKDEKGVFYSITGQGADTPPVGVFIIERETGWL KVTEPLDRERIATYTLFHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEG ALPGTSVMEVTATDADDDVNTYNAAIYTLISQDPELDPKNNMFTINRNTGVISVTTGLD RESFPTYTLVVQAADLQGEGLSTTATAVITVTDNDNPPIFNPTTYKQVPENEANVVIT TLKVTDADAPNTPAWEAVYITLNDGGQFVVTTPVNNNDGILKTAKGLDFEAKQQYILHV AVTNVVPFEVSLTTSTATVTVLDVNEAPIFVPEKRVESDFGVGQEITSYTAQEPD TFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYALIIATDNGSPV ATGTGTTTTLSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPNTSPFTAELTHGA SANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGV CRKAQPVEAGLQIPAILGILGGILALLILLLLLLFLRRRAVVKEPLLPEDDTRDNVYY YDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDEN LKAADTDPTAPPYDSSLVFDYEGSGSEAASSLNSESDDKDQDYDYLNEWGNRFKKLAD MYGGGEDD

[0180] Recombinant proteins were produced as FC fusion or as HIS tagged versions by cloning the respective cDNA into pCDNA4 vector (Invitrogen) and transient transfection in

mammalian HEK293 cells. Purification of the expressed proteins took place by chromatography using Protein A affinity resin for the FC fusion versions and Nickel-NTA resin for HIS tagged proteins. All purified proteins were characterized by SDS-PAGE electrophoresis to verify purity and molecular weight.

[0181] Stable cell lines were developed to be used as immunization antigens, to test binding of antibodies to full length antigen and as target cells in functional T cell assays. Cell lines developed include CHO cells expressing full length human KLRG1 and CHO cells expressing full length cynomolgus KLRG1. Stable cell lines were derived by transfection of CHO cells with pCDNA4 plasmid coding protein of interest. After transfection, the cells were exposed to approximately 500ug/ml of G418 to select for stably integrated plasmid. The cell lines were further characterized by FACS for expression and were sorted to select for homogeneous and stable expression.

[0182] Monoclonal antibodies (MAB) against human KLRG1 were generated by standard immunizations of female BALB/c mice and SJL mice with human and cynomolgus KLRG1, and subsequent hybridoma screening. Several immunization strategies were employed to generate a diverse number of antibody hits. Briefly SJL and Balb/c mice were repeatedly immunized with either cDNA encoding the antigen of interest, recombinant antigen, or CHO cells expressing the antigen of interest. Antigen specific antibody titers were periodically monitored by ELISA and animals were sacrificed when appropriate titers were reached, usually between approximately 1:1000 and approximately 1:10000 dilution factor. Splenocytes from sacrificed mice were fused to mouse myeloma cells to produce hybridoma cells and later cultured and sub-cloned into single cells. Stable clones were scaled up and condition media was harvested and tested for expression of anti-KLRG1 antibodies by ELISA and FACS.

[0183] **Example 2: Selection of anti-KLRG1 antibodies**

[0184] Hybridoma produced antibodies were screened for binding to human KLRG1 ECD and cyno KRG1 ECD. Antibodies with cross reactivity between both antigens were chosen to move forward to the next stage of screening to determine their ability to block the interaction between KLRG1 and E-cadherin. Antibodies were ranked according to their binding EC50 to human and cyno KLRG1 and further selected as hits if they did not interfere with E-cadherin binding in a competition assay. A total of 35 antibodies were selected

according to these criteria and six (6) antibodies were prioritized for functional characterization in cell-based assay.

[0185] Provided below is sequence information for the six selected antibodies that bind to human KLRG1: ABC\_G1D01, ABC\_G1D02, ABC\_G1D03, ABC\_G1D04, ABC\_G1D05 and ABC\_G1D06.

[0186] Table 2 summarizes the amino acid sequences of the heavy and light chain variable regions of the six selected mouse antibodies that bind to human KLRG1, and Table 3 shows the CDR regions for each antibody.

[0187] Table 2: Amino acid sequences of the heavy and light chain variable regions for each mouse anti-KLRG1 antibody

ABC_G1D01-VH	EVQLQQSGPELVKPGASVKMSCKASGYTFTDYNIIHWVKQSHGKSLEWIGFFNPKNGVTIN NQNFKGKAALTVNKSSSTAYMELRRLTSEDSAVYYCARDYYGTAWFAYWGQGLTVTSA (SEQ ID NO:4)
ABC_G1D01-VK	DIVMSQSPSSLAVSVGEKVTMSCRSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRE SGVPDRFTGSGSGTDFLTITSSVKAEDLAVYYCQQFYSPYTFGGGKLEIK (SEQ ID NO:5)
ABC_G1D02-VH	QVQLQQSGAELVRPGTSVKVSKASGYAFTNYFIEWIKRPGQGLEWIGVINPGSGGTNY NEKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCTRPGHFDYWGQGTTLTVSS (SEQ ID NO:6)
ABC_G1D02-VK	EIVLTQSPPTMAASPGEKITITCSASSISSNYLHWYQQKPGFSPKLLIYKTSNLASGVPPRFS GSGSGTSYSLTIGTMEAEDVATYYCQQGNSIPRTFGGGKLEIK (SEQ ID NO:7)
ABC_G1D03-VH	EVQLQQSGPELVKPGASVKMSCKTSGYFTDHNMHWLKQSHGKLEWFGFINPNTGVT RYNQKFNGKATLTINKSSSTAYLRLSLTSEDSAVYYCTRDYYGSAWFAYWGQGLTVTSA (SEQ ID NO:8)
ABC_G1D03-VK	DIVMSQSPASQTVSVGEKVTMCKSSQTLTYSSDQKNYLAWYQQKPGQSPKLLIYWASTR ESGVPDRFTGSGSGTDFLTITSSVKAEDLAVYYCQQYNYPTFGGGKLEIK (SEQ ID NO:9)
ABC_G1D04-VH	EVQLQQSGPELVKPGSSLMMSCKSSGYTFTDYNIIHWVKQSHGKRLEWIGFIDPKNGGTY SEKFKDKATLTINKSSSTAYMELRSLTSEDSAVFYCAPDYGSAWFAYWGQGLTVTSA (SEQ ID NO:10)
ABC_G1D04-VK	DIVMSQSPSSLTVSGENVTMCKSSQNLLYTSNQKNYLAWYQQKPGHSPKLLISWASTR ESGVPDRFTGSGSGTDFLTITSSVKAEDLAVFYCQQYHYPTFGGGKLEIK (SEQ ID NO:11)
ABC_G1D05-VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTHGVHWVRQSPGKLEWLGVIWSSGGSTDY NAAFISRLSIRKDNSKSQVFFKMNSLQTNDAIYYCARLRLPAMDYWGQGTSTVTVSS (SEQ ID NO:12)
ABC_G1D05-VK	QIVLTQSPTIMSASLGERVTMTCTASSVSSTYLHWYQQKPGSSPKLWIYSTNLASGVPAR FSGSGSGTSYSLTSSMEADAATYYCHQYHRSPLSFGAGTKLELK (SEQ ID NO:13)
ABC_G1D06-VH	QVQLQQSGAELVRPGASVTLSCASGYKFSDYEIHWVKQTPVYGLEWIGALEPATGGTAY NPNFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCSMHLAVYWGQGLTVTSA (SEQ ID NO:14)
ABC_G1D06-VK	DVVMTQTPLTSLVTFGQPASISCKSSQSLLYSNGKTYLNWLLQRPQSPKRLIYLVSKLDSG VPDRFTGSGSGTDFLTIKISRVEAEDLGVYVCVQGTHTSPRTFGGGKLEIK (SEQ ID NO:15)

[0188] Table 3: CDR sequences for selected antibodies:

	<b>CDR-H1</b>	<b>CDR-H2</b>	<b>CDR-H3</b>	<b>CDR-L1</b>	<b>CDR-L2</b>	<b>CDR-L3</b>
ABC_G1D01	GYTFTDY (SEQ ID NO:16)	NPKNGV (SEQ ID NO:17)	DYYGTAWFAY (SEQ ID NO:18)	RSSQSLLYSSNQKNYLA (SEQ ID NO:19)	WASTRES (SEQ ID NO:20)	QQFSYPT (SEQ ID NO:21)
ABC_G1D02	GYAFTNY (SEQ ID NO:22)	NPGSGG (SEQ ID NO:23)	PGHFDY (SEQ ID NO:24)	SASSISSNYLH (SEQ ID NO:25)	KTSNLAS (SEQ ID NO:26)	QQGNSIPRT (SEQ ID NO:27)
ABC_G1D03	GYTFTDH (SEQ ID NO:28)	NPNTGV (SEQ ID NO:29)	DYYGSAWFAY (SEQ ID NO:30)	KSSQTLTYSSDQKNYLA (SEQ ID NO:31)	WASTRES (SEQ ID NO:32)	QQYYNYPT (SEQ ID NO:33)
ABC_G1D04	GYTFTDY (SEQ ID NO:34)	DPKNGG (SEQ ID NO:35)	DYYGSAWFAY (SEQ ID NO:36)	KSSQNLLYTSNQKNYLA (SEQ ID NO:37)	WASTRES (SEQ ID NO:38)	QQYYHYPT (SEQ ID NO:39)
ABC_G1D05	GFSLTTH (SEQ ID NO:40)	IWSGGS (SEQ ID NO:41)	LRLPAMDY (SEQ ID NO:42)	TASSSVSSTYLH (SEQ ID NO:43)	STSNLAS (SEQ ID NO:44)	HQYHRSPLS (SEQ ID NO:45)
ABC_G1D06	GYKFSDY (SEQ ID NO:46)	LEPATGG (SEQ ID NO:47)	HLAVY (SEQ ID NO:48)	KSSQSLLYSNGKTYLN (SEQ ID NO:49)	LVSKLDSG (SEQ ID NO:50)	VQGTHSPRT (SEQ ID NO:51)

[0189] The antibodies were further ranked according to the presence of sequence liabilities motifs and are summarized in Table 4.

[0190] Table 4: Sequence liability motifs used to screen antibodies for potential manufacturability problems:

Liability	Motif	Consequence
Unpaired cysteine	C	Adduct formation, activity loss, scrambling, aggregation, process inconsistency
Deamidation	NG	Activity loss, aggregation, process inconsistency
N-glycosylation	NXS/T, X not P	Impact on PK if heavily sialylated, activity loss
Tyrosine sulphation	Neg-Neg-Y-Neg-Neg	Activity loss, process inconsistency
Hydrolysis Asp-Pro	DP	Fragmentation, stability
Methionine oxidation	M	Activity loss, aggregation
Tryptophan oxidation	W	Photosensitivity, activity loss
Deamidation	NS, QG, NN	Activity loss, aggregation, process inconsistency
Asparatate isomerisation	DG, DS, DQ, DK	Activity loss, aggregation

[0191] Table 5 shows examples of humanized constructs for ABC\_HG1D01, ABC\_HG1D02, ABC\_HG1D03. Humanization was carried out by grafting the CDR of the mouse antibodies onto human framework sequences with the highest sequence homology.

[0192] Table 5: Amino acid sequences of variable regions for selected antibodies after humanization:

ABC_HG1D02-VH	QVQLVQSGAEVKKPGSSVKVSCASGYAFTNYFIEWVRQRPGQGLEWWMGVINPGSGGT NYNEKFKGRVTITADKSSSTAYMELSSLRSEDAVYYCARPGHFYWGQGTITVTVSS (SEQ ID NO:52)
ABC_HG1D02-VK	EIVLTQSPPTLTLSPGERATLSCSASSISSNYLHWYQQKPGFAPRLLIYKTSNLSGIPPRFSG SGSGTDFTLISRLEPEDFAVYYCQQGNSIPRTFGQGTKVEIKRTV (SEQ ID NO:53)
ABC_HG1D03-VH	EVQLVQSGAEVKKPGASVKVSCASGYFTDHNMHWVKQATGQGLEWFGFINPNTGVT RYNQKFQGRVTLTINKAISTAYLESSLRSEDAVYYCARDYYGSAWFAYWGQGLTIVTVSS (SEQ ID NO:54)
ABC_HG1D03-VK	DIVMTQSPDSLAVSLGERATINCKSSQTLTYSSDQKNYLAWYQQKPGQPPKLLIYWASTRE SGVPDRFSGSGSGTDFLTISSLQAEDVAVYYCQQYNYPTFGGGTKV (SEQ ID NO:55)

[0193] Back mutations can be introduced in humanized constructs to improve affinity. Furthermore, conservative mutations can be made to the CDR regions to improve affinity, potency, or biophysical characteristics.

[0194] Table 6 summarizes a list a conservative mutation that can be made to the CDR regions.

[0195] Table 6: Exemplary conservative substitutions:

	Conservative		Conservative
Residue	substitution	Residue	Substitution
Ala (A)	Ser (S)	Leu (L)	Ile (I), Val (V)
Arg (R)	Lys (K)	Lys (K)	Arg (R), Gln (Q)
Asn (N)	Gln (Q); His (H)	Met (M)	Leu (L), Ile (I)
Asp (D)	Glu (E)	Phe (F)	Met (M), Leu (L), Tyr (Y)
Cys (C)	Ser (S)	Ser (S)	Thr (T); Gly (G)
Gln (Q)	Asn (N)	Thr (T)	Ser (S), Val (V)
Glu (E)	Asp (D)	Trp (W)	Tyr (Y)
Gly (G)	Pro (P)	Tyr (Y)	Trp (W), Phe (F)
His (H)	Asn (N), Gln (Q)	Val (V)	Ile (I), Leu (L)
Ile (I)	Leu (L), Val (V)	Pro (P)	—

[0196] The antibodies were produced as chimeric by cloning the variable mouse regions onto human IgG constant frameworks and tested in functional assays to determine their functional activity on human T cells and described herein.

[0197] **Example 3: Characterization of antibody binding site by epitope mapping**

[0198] The monoclonal antibodies were found to all bind to the same epitope when binned according to their ability to compete with each other. The binding site of ABC-G1D03 was further analyzed by peptide mapping to identify the specific binding epitope and it was found that it bound to a peptide with the following amino acid sequence: "PLNFSRI" (SEQ ID NO:56). The mapping is illustrated in FIG. 1.

[0199] This sequence can be mapped onto a three-dimensional crystal structure of KLRG1 deposited in the Protein Data Bank (<http://www.rcsb.org/structure/3FF7>) to reveal the binding site. FIG. 2 summarizes the epitope mapping results and highlights that the antibody binding site is distinct from the known ligand binding site. Specifically, FIG. 2 illustrates the three-dimensional representation of KLRG1 (20) binding to E-cadherin (30) derived from the PDB crystal structure 3ff7. A distinct region (40) of KLRG1 highlighted in FIG. 2 corresponds to the binding site for ABC\_G1D03 defined by amino acids "PLNFSRI" (SEQ ID NO:56) on KLRG1. A second region (50) highlighted in FIG. 2 corresponds to the binding interface between KLRG1 and E-cadherin.

[0200] **Example 4: Measurement of antibody binding to cell expressed KLRG1 by FACS**

[0201] Binding of anti-KLRG1 monoclonal antibodies to cells that expressed human and cynomolgus-KLRG1 was carried out by FACS. Chinese hamster ovary (CHO) cells were stably transfected to express full length human KLRG1 (CHO-human-KLRG1) and cynomolgus KLRG1 (CHO-cynomolgus-KLRG1). EC50 values were determined by incubation of varying concentrations of anti-KLRG1 monoclonal antibodies at concentrations ranging from approximately 1 nM to approximately 100 nM, and measuring fluorescence of the labeled cells using an anti-mouse detection antibody directly conjugated with a fluorescent probe. Table 7 summarizes the EC50 binding data measured for selected antibodies.

[0202] Table 7: Binding EC50 of MABs measured by FACS:

SEQ ID	FACS Binding EC50 (nM)	
	Human EC50	Cyno EC50
ABC_G1D01	4.87	3.44
ABC_G1D02	9.11	10.1
ABC_G1D03	6.3	8.63
ABC_G1D04	212.9	7.2
ABC_G1D05	5.15	5.93
ABC_G1D06	72.5	3.4

[0203] **Example 5: Measurement of binding kinetics**

[0204] Binding kinetics of humanized antibodies for human and cynomolgus KLRG1 were determined by Octet® Systems (ForteBio) measurement. The Octet® platform includes instruments, biosensors, reagents, and assay kits for analysis of biomolecular interactions in 96- and 384-well microplates for use in real-time, label-free analysis for determination of affinity, kinetics, and concentration. The experimental set-up includes immobilizing biotinylated recombinant antigen (Human-KLRG-ECD or cynomolgus-KLRG1-ECD) on a streptavidin Octet® sensor to produce antigen loaded sensors. The loaded sensors can then be exposed to varying concentrations of each humanized antibody from approximately 100 nM to approximately 0.1 nM in the OCET® instruments and data collected for approximately 600 seconds to measure association kinetic ( $K_{on}$ ) of the antibody/antigen complex. Thereafter, the sensors can be exposed to a solution of 1 X phosphate buffered saline (PBS) buffer devoid of antibody for approximately 600 seconds to observe dissociation kinetics ( $k_{dis}$ ). The resulting data can then be fitted to a 1:1 binding kinetics model using, for example, ForteBio analysis software to calculate the  $K_D$ . Kinetic binding parameters derived by this method are summarized in Table 8 for three humanized antibodies.

[0205] Table 8: Binding affinity of selected MABs measured by OCTET:

Antigen	Antibody	$k_{on}$ (1/Ms)	$k_{dis}$ (1/s)	$K_D$ (M)
Human KLRG1	ABC_HG1D0 2	5.41E+5	3.07E-5	5.67E-11
	ABC_HG1D0 3	3.80E+5	5.91E-5	1.56E-10
	ABC_HG1D0 4	5.05E+5	1.25E-4	2.48E-10

Cyno KLRG1	ABC_HG1D0 2	3.67E+5	1.42E-4	3.88E-10
	ABC_HG1D0 3	6.27E+5	3.82E-5	6.09E-11
	ABC_HG1D0 4	5.85E+5	4.74E-5	8.10E-11

[0206] **Example 6: Characterization of ADCC activity for KLRG1 binding antibodies**

[0207] This example demonstrates that non-blocking antibodies against KLRG1 have no effect on T cell activity and therefore are functionally different from blocking antibodies, which interfere with the interaction between KLRG1 and its ligands and result in activating effect on human CD8+ T cell by measured by production of interferon gamma (IFN-gamma).

[0208] Here KLRG1 blocking antibodies are defined as binding to KLRG1 extracellular domain and effectively competing with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1. Conversely, non-blocking antibodies are defined as antibodies that bind to KLRG1 extracellular domain but do not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1.

[0209] To demonstrate the differential functional effect of KLRG1 blockade on cells of the immune system, CD8+ T cells were isolated from healthy donors and tested in co-culture with a CHO cell line co-expressing a CD3 agonist and an E-cadherin (eAPC). The assay works by providing T cells with two (2) competing signals where CD3 stimulation is counteracted by the inhibitory effect of E-cadherin. When KLRG1 signaling is blocked by anti-KLRG1 antibodies, the inhibitory signal is disrupted, and T cells are activated according to their interaction with the CD3 agonist expressed on the cell surface. Interferon gamma secretion is measured by ELISA and results summarized in FIG. 3. This data demonstrate that E-cadherin has an inhibiting effect on human T cells which can be reversed by blockade of KLRG1 signaling with blocking antibodies. It also shows that non-blocking antibodies do not have stimulating effect.

[0210] **Example 7: Selective *in vivo* depletion of KLRG1 positive T cells with non-blocking anti-KLRG1 antibody in non-human primate**

[0211] This example demonstrates that non-blocking anti-KLRG1 antibodies can be used to selectively deplete KLRG1 positive T cells while sparing other lymphocytes necessary for

normal immune function, such as regulatory T cells and naïve T cells. In the present example, the antibody ABC-HG1D03 was produced in an afucosylated form and administered to cynomolgus monkeys via a subcutaneous route of administration.

[0212] Table 9 summarizes the study design, including number of animals per cohort, dosing amount, and dosing regimen:

Group	Test Material	Dose level (mg/kg/day)	Doses (Days)	Main study (28 days)	
				Male	Female
1	Control	0	1,8,15,22	5	5
2	ABC-HG1D03	0.1	1,8	3	3
3	ABC-HG1D03	0.3	1,8	3	3
4	ABC-HG1D03	10	1,8,15,22	3	3
5	ABC-HG1D03	30	1,8,15,22	5	5

[0213] In order to monitor the effect of afucosylated ABC-HG1D03 on different immune cells, flow cytometry was used to immunophenotype circulating lymphocytes in cynomolgus monkey whole blood.

[0214] FIG. 4 highlights the identification scheme for KLRG1 positive cells and the classification of T cells as naïve (CCR7+) or effector (CCR7-). As established in published data (Koch et al., 2008, Legat et al., 2013), the flow cytometry data of FIG. 4 shows that KLRG1 is expressed predominantly on a subset of CCR7- effector T cells. The flow cytometry data of FIG. 4 also shows that KLRG1 is differentially expressed on effector T cells (TEM and TEMRA), which are CCR7-, compared to naïve T cells (TN and TCM), which are CCR7+. One skilled in the art will recognize that central memory T cells (TCM) express CCR7 while effector memory (TEM) T cells lack expression of CCR7. In humans, but not in mice, there is a third T cell memory subset, TEMRA, that includes cells that express CD45RA but lack expression of CCR7.<sup>2</sup>

<sup>2</sup> (Willinger, T. et al. Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets. *J Immunol* 2005; 175:5895-5903; doi: 10.4049/jimmunol.175.9.5895 <http://www.jimmunol.org/content/175/9/5895>

[0215] The flow cytometry data of FIG. 5 exemplifies the depletion effect of *in vivo* administration of ABC-HG1D03 to cynomolgus monkeys by comparing a control animal with an animal dosed at 30 mg/kg. This data shows the depletion of KLRG1+ cells in the ABC-HG1D03 dosed animal compared to control, demonstrating the selective depletion of effector T cells and not naïve T cells. The flow cytometry analysis of CD8 T cells from non-human primate whole blood highlights the depletion effect of ABC-HG1D03 on KLRG1+ T cells. Notably, the KLRG1 positive cells correspond to the effector phenotype and administration of ABC-HG1D03 results in full, yet selective depletion of this compartment.

[0216] The average % of KLRG1+ CD8 T cells in all dosed animals are plotted in FIG. 6. As shown, there is a dose dependent effect of ABC-HG1D03 on depletion of KLRG1+ CD8 T cells.

[0217] FIG. 7 exemplifies the regulatory T cell sparing effect from the administration of ABC-HG1D03 to cynomolgus monkeys. The data shows no effect over a period of 28 days of KLRG1 depleting treatment on regulatory T cells for the dosing groups tested. Tregs can be viewed as another subset of CD4 T cells whose role is to regulate and suppress, rather than to induce and promote, immune responses.

[0218] One skilled in the art will appreciate further features and advantages of the disclosure based on the above-described embodiments. Accordingly, the disclosure is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety. Citation of references is not an admission that these references are prior art to the present disclosure.

#### REFERENCES

1. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? *Nat Rev Immunol.* 2011; 11(4):289-95.
2. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. *Studies in repeated muscle biopsies. Brain: a journal of neurology.* 2000; 123 ( Pt 10):2030-9.

3. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, et al. Consensus nomenclature for CD8 T cell phenotypes in cancer. *Oncoimmunology*. 2015; 4(4):e998538.
4. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. *Ann Neurol*. 1984; 16(2): 193-208.
5. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. *Ann Neurol*. 1986; 19(2): 112-25.
6. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. *Ann Neurol*. 1988; 23(2): 168-73.
7. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. *Cancer Res*. 2009; 69(21):8412-9.
8. Betjes MG, Meijers RW, de Wit EA, Weimar W, Litjens NH. Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection. *Transplantation*. 2012; 94(1):63-9.
9. Bisping G, Luger N, Lutke-Brintrup S, Pauels HG, Schurmann G, Domschke W, et al. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. *Clinical and experimental immunology*. 2001; 123(1):15-22.
10. Blanco P, Viallard JF, Pellegrin JL, Moreau JF. Cytotoxic T lymphocytes and autoimmunity. *Current opinion in rheumatology*. 2005; 17(6):731-4.
11. Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, et al. Tumor-infiltrating, interleukin-33 -producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. *Hepatology*. 2015; 61(6): 1957-67.
12. Bueno V, Pestana JO. The role of CD8+ T cells during allograft rejection. *Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al]*. 2002; 35(11): 1247-58.

13. Carvalho H, Duarte C, Silva-Cardoso S, daSilva JA, Souto-Carneiro MM. CD8 T cell profiles in patients with rheumatoid arthritis and their relationship to disease activity. *Arthritis & rheumatology*. 2014; 37(2):363-71.
14. D'Asaro M, Dieli F, Caccamo N, Musso M, Porretto F, Salerno A. Increase of CCR7-CD45RA+ CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. *Leukemia*. 2006; 20(3):545-7.
15. Faustman DL, Davis M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. *Journal of molecular medicine*. 2009; 87(12): 1173-8.
16. Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. *Ann Neurol*. 2009; 66(2): 132-41.
17. Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. *Brain : a journal of neurology*. 2016; 139: 1348-1360.
18. Guthmann MD, Tal M, Pecht I. A new member of the C-type lectin family is a modulator of the mast cell secretory response. *Int Arch Allergy Immunol*. 1995; 107(1-3):82-6.
19. Hijnen D, Knol EF, Gent YY, Giovannone B, Beijin SJ, Kupper TS, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. *J Invest Dermatol*. 2013; 133(4):973-9.
20. Hofmann M, Schweier O, Pircher H. Different inhibitory capacities of human and mouse KLRG1 are linked to distinct disulfide-mediated oligomerizations. *Eur J Immunol*. 2012; 42(9):2484-90.
21. Kita H. Autoreactive CD8-specific T-cell response in primary biliary cirrhosis. *Hepatology research : the official journal of the Japan Society of Hepatology*. 2007; 37 Suppl 3:S402-5.
22. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. *Immun Ageing*. 2008;5:6.
23. Lamy T, Loughran TP, Jr. How I treat LGL leukemia. *Blood*. 2011; 117(10):2764-74.
24. Legat A, Speiser DE, Pircher H, Zehn D, Furtak SA. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. *Front Immunol*. 2013; 4:455.

25. Melis L, Van Praet L, Pircher H, Venken K, Elewaut D. Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-alpha production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. *Ann Rheum Dis*. 2014; 73(6): 1223-31.
26. Muller S, Lory J, Corazza N, Griffiths GM, Z'Graggen K, Mazzucchelli L, et al. Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. *The American journal of pathology*. 1998; 152(1):261-8.
27. Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Y, et al. Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases. *Clinical and experimental immunology*. 2009; 155(2): 166-72.
28. Schirmer M, Goldberger C, Wurzner R, Duftner C, Pfeiffer KP, Clausen J, et al. Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis. *Arthritis research*. 2002;4(1):71-6.
29. Takata K, Hong ME, Sitthinamsuwan P, Loong F, Tan SY, Liao JY, et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia. *The American journal of surgical pathology*. 2015; 39(1): 1-12.
30. Tessmer MS, Fugere C, Stevenaert F, Naidenko OV, Chong HJ, Leclercq G, et al. KLRG1 binds cadherins and preferentially associates with SHIP-1. *International immunology*. 2007; 19(4):391-400.
31. Trevino MA, Teixeira E, Bragado R. CD8+ T cells oligoclonally expanded in synovial fluid at onset of spondyloarthritis selectively proliferate in response to self-antigens: characterization of cell specificities in nonclonal populations. *The Journal of rheumatology*. 2004; 31(10): 1962-72.
32. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). *Blood*. 2002;100(10):3698-702.
33. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med*. 2014; 20(9): 1043-9.

34. Willinger, T. et al. Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets. *J Immunol* 2005; 175:5895-5903; doi: 10.4049/jimmunol.175.9.5895 <http://www.jimmunol.org/content/175/9/5895>.
35. Yamauchi C, Fujii S, Kimura T, Kuwata T, Wada N, Mukai H, Matsumoto N, Fukayama M, Ochiai A. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells. *Int J Cancer*. 2011; 128(9):2125-37.
36. Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behcet's uveitis. *Clinical and experimental immunology*. 2004; 137(2):437-43.
37. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. *Journal of immunology*. 2004; 172(8):5120-7.

What is claimed is:

1. A method of depleting KLRG1 expressing T cells and/or NK cells in a subject in need thereof without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, comprising:

delivering to a subject an effective amount of antibody, or a fragment thereof, wherein the antibody, or fragment thereof, specifically binds to the extracellular domain of KLRG1 but does not compete with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, thereby depleting KLRG1 expressing T cells in the subject.

2. The method of claim 1,

wherein the antibody, or a fragment thereof, comprises a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or

wherein the antibody, or a fragment thereof, comprises a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

3. The method of claim 1, wherein the KLRG1 comprises human KLRG1 or Cyno KLRG1.

4. The method of claim 1, wherein the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment thereof.

5. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, specifically binds the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five contiguous amino acids.

6. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical thereto.

7. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical thereto.
8. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical thereto.
9. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical thereto.
10. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical thereto.
11. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical thereto.
12. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:10, or a sequence approximately at least 90% identical thereto.
13. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical thereto.
14. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical thereto.
15. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical thereto.

16. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical thereto.
17. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical thereto.
18. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a chimeric antibody, or a fragment thereof.
19. The method of claim 4, wherein the monoclonal antibody, or a fragment thereof, comprises a humanized antibody or a fragment thereof.
20. A method of treating a disorder associated with excess KLRG1 expressing T cells in a subject in need thereof, comprising:  
delivering to a subject a therapeutically effective amount of an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, and depletes KLRG1 expressing T cells,  
wherein the delivery to the subject depletes the excess KLRG1 expressing T cells,  
wherein the delivery does not release checkpoint inhibition and subsequent activation of pathogenic CD8<sup>+</sup> cytotoxic T and/or NK cells directed to self-tissues, thereby treating the disorder,  
wherein the antibody, or a fragment thereof, comprises:  
a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or  
wherein the antibody, or a fragment thereof, comprises:  
a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.
21. The method of claim 20,  
wherein the disorder comprises a transplant disorder, and

wherein the delivery to the subject depletes KLRG1 expressing pathogenic T cells and/or NK cells attacking transplanted tissues in the subject.

22. The method of claim 20,  
wherein the disorder comprises an autoimmune disease, and  
wherein the delivery to the subject depletes KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject.

23. A method of treating cancer in a subject, wherein the cancer comprises cancer cells that express KLRG1, the method comprising:

delivering to a subject a therapeutically effective amount of an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1,

wherein the delivery to the subject depletes the cancer cells expressing KLRG1, and  
wherein the delivery does not release checkpoint inhibition and subsequent activation of pathogenic CD8<sup>+</sup> cytotoxic T and/or NK cells directed to self-tissues,

wherein the antibody, or a fragment thereof, comprises:

a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or

wherein the antibody, or a fragment thereof, comprises:

a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

24. An adjunct therapy for treatment of cancer in a subject, wherein the subject is undergoing checkpoint therapy, regardless of whether the cancer expresses KLRG1, the adjunct therapy comprising:

delivering to a subject a therapeutically effective amount of an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 without interfering with binding by E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1,

wherein the delivery depletes KLRG1 expressing pathogenic T cells and/or NK cells attacking self-tissues in the subject,

wherein the antibody, or a fragment thereof, comprises:

a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or

wherein the antibody, or a fragment thereof, comprises:

a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

25. A method of depleting KLRG1 expressing cells in a mixed population of cells, wherein the KLRG1 expressing cells comprise one or more cells selected from the group consisting of T cells and/or NK cells and/or cancer cells, the method comprising:

delivering to a mixed population of cells an effective amount of an antibody, or a fragment thereof, that specifically binds to KLRG1 and depletes KLRG1 expressing T cells and/or NK cells and/or cancer cells, thereby depleting KLRG1 expressing T cells and/or NK cells and/or cancer cells in the mixed population of cells,

wherein the antibody, or a fragment thereof, comprises:

a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or

wherein the antibody, or a fragment thereof, comprise:

a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

26. An antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLGR1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLGR1, and depletes cells expressing KLGR1 when administered to a subject.

27. The antibody, or a fragment thereof, of claim 26,

wherein the antibody, or a fragment thereof, comprises:

a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; and/or

wherein the antibody, or a fragment thereof, comprises:


a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

28. The antibody, or a fragment thereof, of claim 26, wherein the KLRG1 comprises human KLRG1 or Cyno KLRG1.
29. The antibody, or a fragment thereof, of claim 26, wherein the antibody, or a fragment thereof, comprises a monoclonal antibody, or a fragment or derivative thereof.
30. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, specifically binds the epitope PLNFSRI (SEQ ID NO:56), or a fragment thereof, comprising at least five contiguous amino acids.
31. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, or a sequence approximately at least 90% identical thereto.
32. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:5, or a sequence approximately at least 90% identical thereto.
33. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6, or a sequence approximately at least 90% identical thereto.
34. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:7, or a sequence approximately at least 90% identical thereto.
35. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8, or a sequence approximately at least 90% identical thereto.
36. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:9, or a sequence approximately at least 90% identical thereto.


37. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:10, or a sequence approximately at least 90% identical thereto.
38. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:11, or a sequence approximately at least 90% identical thereto.
39. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:12, or a sequence approximately at least 90% identical thereto.
40. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:13, or a sequence approximately at least 90% identical thereto.
41. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:14, or a sequence approximately at least 90% identical thereto.
42. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:15, or a sequence approximately at least 90% identical thereto.
43. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment thereof, comprises a chimeric antibody, or a fragment thereof.
44. The antibody, or a fragment thereof, of claim 29, wherein the monoclonal antibody, or a fragment, thereof comprises a humanized antibody, or a fragment thereof.
45. A pharmaceutical composition, comprising the monoclonal antibody, or a fragment thereof, of claim 29 and a pharmaceutically acceptable carrier.
46. A kit, comprising the monoclonal antibody, or a fragment thereof, of claim 29 and instructions for use.
47. A method of selectively depleting KLRG1 expressing CD8 effector T cells, but not naïve T cells or regulatory T cells, comprising:

delivering to a subject an effective amount of antibody, or a fragment thereof, wherein the antibody, or fragment thereof, specifically binds to the extracellular domain of KLRG1 but does not compete with binding of at least one of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG1, thereby selectively depleting KLRG1 expressing CD8 effector T cells.

FIG. 1




**FIG. 2**



**FIG. 3**

Sample name	IFN $\gamma$ (pg/ml), replicate #1	IFN $\gamma$ (pg/ml), replicate #2
CD8 positive control	1624.09	1401.42
Isotype	390.02	355.94
mAb023	1579.71	1389.6
ABC_G1D01	NA	NA
ABC_G1D02	763.71	628.25
ABC_G1D03	919.95	772.32
ABC_G1D04	NA	NA
ABC_G1D05	804.64	793.9
ABC_G1D06	656.08	758.43



**FIG. 4**




FIG.5




FIG. 6





FIG. 7

4793786.1



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/27498

## A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61P 35/00, A61P 35/04, A61K 39/395, A61K 38/00, C12N 15/85 (2020.01)

CPC - C07K 16/2851, C07K 16/2818, A61K 2039/505, A61K 2039/507, C07K 2317/21, C07K 16/2896, C12N 15/1138

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2019/0085083 A1 (THE BRIGHAM AND WOMEN'S HOSPITAL) 21 March 2019 (21.03.2019) Abstract; Claim 1; para [0009]; para [0012]; para [0035]; para [0089]; para [0119];	1, 3-4, 18-19
Y	para [0154]; para [0188-0189]; para [0267]; para [0292]; para [0296]; SEQ ID NO:2	5, 47
A		2, 6, 20-25
Y	US 2017/0260282 A1 (JANSSEN BIOTECH, INC.) 14 September 2017 (14.09.2017) Abstract; para [0235]; para [0239]; para [0241]	5
Y	WO 2018/053264 A2 (THE BRIGHAM AND WOMEN'S HOSPITAL INC. et al.) 22 March 2018 (22.03.2018) Abstract	47
A	WO 2008/140653 A2 (TALIGEN THERAPEUTICS, INC.) 20 November 2008 (20.11.2008) para [0065], SEQ ID NO: 10	2, 6, 20-25

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

19 August 2020

Date of mailing of the international search report

08 SEP 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/27498

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
- 2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
- 3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
---Please see continuation in first extra sheet -----

- 1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
- 4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-6, 18-25, 47, limited to antibody with VH of SEQ ID NO:4

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/US 20/27498

Continuation of Box No. III. Observations where unity of invention is lacking.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+, Claims 1-25, 47, directed to a method of depleting KLRG 1 expressing T cells and/or NK cells in a subject in need thereof without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG 1, treating a disorder associated with excess KLRG1 expressing T cells, and an adjunct therapy for treatment of cancer. The method will be searched to the extent that the anti-KLRG1 antibody encompasses a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4 (note, this is the first claimed sequence for anti-KLRG1 antibody). It is believed that claims 1-6, 18-25, 47 encompass this first named invention, and thus these claims will be searched without fee to the extent that the anti-KLRG1 antibody comprises a VH region of SEQ ID NO:4. Additional method(s) comprising additional antibodies(s) will be searched upon the payment of additional fees. Applicants must specify the claims that encompass any additionally elected method(s) comprising additional antibodies(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. An exemplary election would be a method comprising an anti-KLRG1 antibody encompassing a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5 (claims 1-5, 7, 18-25, 47).

Group II+, claims 26-46, directed to an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1, and depletes cells expressing KLRG1 when administered to a subject. Group II+ will be searched upon payment of additional fees. The antibody may be searched, for example, to encompass a heavy chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:4 for an additional fee and election as such. It is believed that claims 26-31, 43-46 read on this exemplary invention. Additional antibodies will be searched upon the payment of additional fees. Applicants must specify the claims that encompass any additionally elected antibodies. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. Another exemplary election would be an antibody fragment encompassing a light chain variable region comprising three complementarity determining regions of an amino acid sequence of: SEQ ID NO:5 (claims 26-30, 32, 43-46).

The inventions listed as Groups I+ and II+ do not relate to a single special technical feature under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

**Special technical features**

The inventions of Group I+ and II+ each include the special technical feature of a unique amino acid sequence. Each amino acid sequence encodes a unique peptide, and is considered a distinct technical feature. Additionally, Group I+ has the special technical feature of a method of depleting KLRG 1 expressing T cells and/or NK cells in a subject in need thereof without interfering with binding of E-cadherin, N-cadherin, or R-cadherin to the extracellular domain of KLRG 1, treating a disorder associated with excess KLRG1 expressing T cells, and an adjunct therapy for treatment of cancer, that is not required by Group II+.

Group II+ has the special technical feature of a composition comprising an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1, that is not required by Group I+.

**Common technical features**

No technical features are shared between the antibody amino acid sequences in each of Groups I+ and II+ and, accordingly, these groups lack unity a priori.

Additionally, even if Groups I+ and II+ were considered to share the technical features of including: an antibody, or a fragment thereof, that specifically binds to an extracellular domain of KLRG1 but does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1; and depletes cells expressing KLRG1 when administered to a subject; these shared technical features are previously disclosed by US 2019/0085083 A1 to The Brigham and Women's Hospital, (hereinafter 'TBWH').

-----please see continuation on next sheet-----

Continuation of Box No. III. Observations where unity of invention is lacking.

-----continued from previous sheet-----

TBWH teaches an antibody that specifically binds to an extracellular domain of KLRG1 and depletes cells expressing KLRG1 when administered to a subject (Abstract - 'A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent'; para [0012] - 'The invention provides a method of treating a melanoma comprising administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, wherein the binding agent is an antibody or antigen binding fragment thereof, or antibody mimetic that binds the extracellular domain of human KLRG1 and/or human E-cadherin, N-cadherin, or R-cadherin, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells.'; para [0035] - 'In various embodiments, the KLRG1 is the extracellular domain of human KLRG1.'; para [0296] - 'FIGS. 26A and B show inhibition of lung metastases in 4T1 breast cancer murine model with anti-KLRG1 antibody, as evidenced by reduction in lung nodule counts (FIG. 26A) and lung weights (FIG. 26B).'). TBWH does not expressly teach anti-KLRG1 antibody does not compete with E-cadherin, N-cadherin, or R-cadherin binding to KLRG1. However, since TBWH teaches mouse-human chimeric antibodies with no dose dependent neutralization of E-cadherin (para [0292] - 'FIG. 24 presents the results of the three mouse-human chimeric antibodies neutralizing hE-cadherin/hKLRG1 binding. The concentration of soluble E-cadherin was fixed at the EC80 value of 100 nM, while the concentration of chimeric antibodies was varied. Chimeric antibody HYB03 shows a dose dependent neutralization (IC50 of 1.1 nM). Chimeric antibodies HYB01 and HYB02 show effectively no dose dependent neutralization (IC50 NA).'), it would have been obvious to one of ordinary skill in the art that the chimeric antibodies HYB01 and HYB02 bind KLRG1 in a manner that does not compete with E-cadherin binding to KLRG1 because these antibodies fail to show dose-dependent neutralization of E-cadherin.

As the technical features were known in the art at the time of the invention, they cannot be considered special technical features that would otherwise unify the groups.

Therefore, Group I+ and II+ inventions lack unity under PCT Rule 13 because they do not share the same or corresponding special technical feature.